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Fotoferesebehandling av pasienter med CTCL eller GVHD 
 
Fotoferese (extracorporeal photochemotherapy, ECP) har blitt en akseptert 
behandling av enkelte T celle medierte tilstander, som kutant T celle lymfom (CTCL) 
og Graft-vs-Host disease (GVHD). Blant CTCL pasientene så har omtrent halvparten 
en positiv effekt av behandlingen. Det finnes imidlertid ingen gode prediktive 
markører for respons. I Paper I har vi evaluert responsraten ved ECP hos pasienter 
med CTCL som har blitt behandlet på St. Olavs Hospital, i tillegg til å undersøke flere 
potensielle prediktive markører. 7 av 16 pasienter ble klassifisert som respondere på 
ECP-behandling. Hverken T celle klonalitet eller noen av serummarkørene som ble 
undersøkt kunne benyttes som prediktiv markør før behandlingsstart, men det kan se 
ut til at forandringer i enkelte av markørene etter 6 måneders behandling korrelerer 
med klinisk respons evaluert etter 12 måneders behandling. 
 
Virkningsmekanismen til ECP er fortsatt ikke fullt ut kjent. Det man vet er at 
behandlingen induserer apoptose av lymfocytter. Inntil nylig har man trodd at 
monocytter ikke går i apoptose av behandlingen, men heller aktiveres og 
differensieres til umodne dendrittceller (DC), som effektivt fagocytterer og 
presenterer antigen til immunforsvaret. Ved CTCL har man derfor trodd at en 
cytolytisk, tumorspesifikk immunrespons settes i gang. I Paper II har vi undersøkt 
hvordan ECP påvirker lymfocytter, monocytter og umodne DC. Vi fant at alle cellene 
går i apoptose kort tid etter ECP-behandling, samt har redusert evne til å differensiere. 
Vi mener derfor at det er sannsynlig at den terapeutiske effekten av ECP heller 
skyldes regulatoriske mekanismer in vivo som følge av infusjon av apoptotiske celler. 
Vi viser videre at 30 Gy bestråling induserer apoptose av lymfocytter, men påvirker 
tilsynelatende ikke monocytter og DC. Dette kan muligens utnyttes til å øke tumor 
fagocytose ex vivo og dermed effektivisere antigen presentasjon in vivo. 
 
GVHD oppstår når T celler fra en donor angriper mottakeren. Det er foreslått at ECP 
trigger visse toleransemekanismer, som hemming av pro-inflammatoriske cytokiner, 
samt økt produksjon av anti-inflammatoriske cytokiner og regulatoriske T celler 
(Treg). Det kan imidlertid virke paradoksalt at den samme behandlingen skal sette i 
gang en tumorspesifikk, cytolytisk immunrespons mot lymfomceller hos CTCL 
pasienter, mens den fører til økt regulatorisk aktivitet hos GVHD pasienter. I Paper 
III har vi sammenlignet andelen av sirkulerende Treg celler hos pasienter med CTCL 
eller GVHD. Ved CTCL var det dobbelt så høy forekomst av Treg celler i sirkulasjon, 
sammenlignet med GVHD og normal kontroller, muligens en respons som er 
involvert i nedregulering av lymfomceller. I tillegg undersøkte vi også om det var en 
målbar forandring av et utvalg cytokiner i serum før og etter ECP. Det anti-
inflammatoriske cytokinet TGF-β var nær tre ganger høyere hos GVHD pasientene og 
kan indikere høy Treg aktivering. Begge pasientgruppene hadde en økning av TGF-β 
under behandlingen. Dette kan tolkes som en forbedret Treg funksjon hos begge 
pasientgruppene. 
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Hovedveileder: Prof. Torolf Moen  
Finansieringskilde: Institutt for LBK, DMF, NTNU 
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Summary in Norwegian 
Extracorporeal photokjemoterapi (ECP) har blitt akseptert som behandling av enkelte T celle 
medierte tilstander, som kutant T celle lymfom (CTCL) og Graft-vs-Host disease (GVHD). 
Ved CTCL responderer omtrent halvparten av pasientene på behandlingen. Det finnes 
imidlertid ingen gode prediktive markører for respons, og en slik markør ville naturlig nok 
være av stor nytte. I Paper I har vi evaluert responsraten ved ECP hos pasienter med CTCL 
som har blitt behandlet på St. Olavs Hospital, i tillegg til å undersøke flere andre potensielle 
prediktive markører. 7 av 16 pasienter ble klassifisert som respondere på ECP-behandling. 
Hverken T celle klonalitet eller noen av serummarkørene som ble undersøkt kunne benyttes 
som prediktiv markør før behandlingsstart, men det kan se ut til at forandringer i enkelte av 
markørene etter 6 måneders behandling korrelerer med klinisk respons evaluert etter 12 
måneders behandling. 
 
Virkningsmekanismen til ECP ved CTCL er fortsatt ikke kjent. ECP induserer apoptose av 
lymfocytter. Inntil nylig har man trodd at monocytter ikke går i apoptose av behandlingen, 
men heller aktiveres og differensieres til umodne dendrittceller (DC). Disse er effektive 
fagocytter og presenterer fagocytert tumor antigen til immunforsvaret. Slik har man trodd at 
en cytolytisk tumorspesifikk immunrespons settes i gang. I Paper II har vi undersøkt hvordan 
ECP påvirker monocytter og umodne DC når det gjelder indusering av apoptose samt evne til 
å differensiere etter behandling. Vi fant at både lymfocytter, monocytter og umodne DC går i 
apoptose innen 72 timer etter ECP-behandling. Siden de også har en redusert evne til å 
differensiere etter ECP er det sannsynlig at den terapeutiske effekten av ECP heller skyldes in 
vivo mekanismer som følge av infusjon av apoptotiske celler, fremfor infusjon av monocytter 
som er indusert til å differensiere til umodne DC. Monocytter og DC som ble bestrålt med 
30Gy gamma bestråling, dvs doser som induserer apoptose av lymfocytter, ser ut til å være 
uaffisert av denne behandlingen når det gjelder overlevelse og evne til differensiering. 
 
GVHD oppstår når allogene effektor T celler fra en donor angriper mottakeren. Det er 
foreslått at ECP trigger visse toleransemekanismer, som hemming av pro-inflammatoriske 
cytokiner, stimulering av regulatoriske T celler (Treg) og produksjon av anti-inflammatoriske 
cytokiner. Det kan imidlertid virke paradoksalt at den samme behandlingen skal sette i gang 
en tumorspesifikk, cytolytisk immunrespons mot lymfomceller hos den ene pasientgruppen, 
mens den fører til økt regulatorisk aktivitet hos GVHD pasienter. I Paper III har vi 
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sammenlignet den relative andelen av sirkulerende Treg celler hos pasienter med CTCL eller 
GVHD. Vi fant her at CTCL pasientene har nær dobbelt så høy forekomst av Treg celler i 
sirkulasjon, sammenlignet med GVHD og normal kontroller. I tillegg undersøkte vi også om 
det var en målbar forandring av cytokiner i serum før og etter ECP. Før behandling var det 
anti-inflammatoriske cytokinet TGF-β i gjennomsnitt tre ganger høyere hos GVHD 
pasientene, sammenlignet med CTCL. Begge pasientgruppene hadde en liten, men signifikant 
økning av TGF-β etter behandling. Disse resultatene kan tolkes som en forbedret Treg 
funksjon som resultat av behandlingen. Økt TGF-β kan indikere høy Treg aktivering hos 
GVHD pasientene, mens en forhøyet relativ andel Treg celler hos CTCL pasientene kan 
tolkes som en respons som muligens er involvert i nedregulering av lymfom cellene. 
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Summary in English 
Extracorporeal photochemotherapy (ECP) has been accepted as a standard therapy in certain 
T cell mediated conditions, such as cutaneous T cell lymphomas (CTCL) and Graft-vs-Host 
Disease (GVHD). In CTCL approximately one half of these patients respond to the treatment. 
However, predictive criteria for selecting patients who will respond to ECP are mainly 
lacking. In Paper I, we have evaluated the response rate to ECP in CTCL patients treated at 
St. Olavs Hospital, as well as investigated several potential predictive markers. Seven out of 
16 patients evaluated were classified as responders to ECP. Neither T cell clonality nor any of 
the serum markers assessed pre-treatment could reliably predict the response to ECP 
treatment. However, the individual relative changes in some of the serum markers assessed 
during 6 months of ECP treatment coherently displayed correlation to the clinical response as 
evaluated after 12 months of ECP treatment. 
 
The mechanism of effect in ECP therapy is somewhat unclear. ECP has been shown to induce 
apoptosis in lymphocytes. Until recently the prevailing opinion has been that the monocytes 
were mainly not affected by this treatment, but rather were activated and differentiated into 
immature dendritic cells (DC), capable to phagocytize apoptotic CTCL-cells, and initiate a 
cytolytic tumour specific immune response. In Paper II we have tried to elucidate the effect 
of ECP on monocytes and immature DC, and followed the ability of the cells to differentiate 
and survive post treatment. We found that lymphocytes, monocytes and immature DC become 
apoptotic within 72 hours when treated with ECP. Since monocytes and immature DC seem to 
have a reduced ability to differentiate after ECP treatment, it is likely that the therapeutic 
effect of ECP is caused by in vivo effects of reinfused apoptotic cells, rather than by infusion 
of monocytes induced to differentiate into immature DC. Monocytes and DC treated with 
30Gy gamma irradiation, i.e. doses that induce apoptosis in lymphocytes, were unaffected 
regarding survival and ability to differentiate post-treatment. 
 
GVHD is mainly mediated by allogeneic effector T cells recognizing the transplant recipient 
as foreign. ECP is reported to be triggering certain tolerance mechanisms, such as inhibition 
of pro-inflammatory cytokines, stimulation of regulatory T cells (Treg) and production of 
anti-inflammatory cytokines. It may, however, seem like a paradox that ECP initiates a 
tumour specific, cytolytic response against lymphoma cells in one condition, whereas it 
increases the regulatory function in another. In Paper III we have compared the relative 
__________________________________________________________________________________________ 
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levels of circulating Treg cells in patients with CTCL or GVHD. We found that the relative 
amount of Treg cells was twice as high in CTCL compared to GVHD and healthy controls. In 
addition, we investigated whether there were any measurable changes in serum cytokine 
levels during ECP therapy.  Pre-treatment, the anti-inflammatory cytokine TGF-β was on 
average 3 times higher in GVHD than in CTCL. Both patient groups had a small, but 
significant increase in TGF-β after treatment. Our results indicate a strengthened Treg 
function as a result of ECP. Elevated TGF-β may indicate high Treg activation in GVHD, 
whereas an increased number of Treg cells in CTCL could be interpreted as a response that 
possibly is involved in down-regulating the lymphoma cells. 
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“Live as if you were to die tomorrow. Learn as if you were to live forever.” 
Mohandas Karamchand Gandhi (1869 – 1948) 
 
 
 
 
 
Introduction 
 
Historical aspects 
Therapy for dermatological diseases based on non-ionizing electromagnetic radiation 
(especially long-wave UV radiation) is a concept developed in a subspeciality of medicine 
that has become known as photomedicine, and the combined use of electromagnetic energy 
and a photoactive drug has been termed photochemotherapy. The combination of psoralens 
and UVA-light (PUVA) was first reported as a treatment for psoriasis in 1974 [1], but the 
practice is in fact almost 4000 years old. In the ancient world, especially in Egypt and India, it 
has been used since 1200-2000BC as a therapy for the common dermatological disease 
vitiligo, also known as leukoderma or “white leprosy”, causing depigmentation in patches of 
the skin. An extract made from the leaves, seeds or roots of psoralen-containing plants such as 
Ammi majus (Fig. 1), originating in the Nile River Valley in Egypt, and Psoralea corylifolia 
in India, was either ingested or applied to the affected skin areas before exposing the skin to 
the bright sunlight [2]. 
 
Fig. 1 Ammi majus, originating in the Nile River Valley in Egypt. (Also known as Bishop’s weed, Bullwort, 
Greater ammi, Lady’s lace and Laceflower. “Kongeskjerm” in Norwegian). 
 
Niels Finsen received the Nobel Prize in Medicine in 1903 for his successful treatment of 
lupus vulgaris with phototherapy, which marked the beginning of modern phototherapy. 
Almost 50 years later, the active ingredient of the ammi majus plant was isolated by an 
Egyptian pharmacologist and characterized as 8-methoxypsoralen (8-MOP), which was later 
shown to be photoactivated by exposure to UV-light [3]. In addition to having an effect on 
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psoriasis [1], PUVA was reported by Gilchrest to be effective in Cutaneous T cell lymphoma 
(CTCL) [4]. Soon it was demonstrated that photoactivation of 8-MOP induced T cell 
apoptosis by forming interstrand crosslinks in DNA [5]. A study from Yale University 
published in 1987 by Edelson and colleagues reported a favourable effect of extracorporeal 
photochemotherapy (ECP or photopheresis) in CTCL[6]. This formed the basis for approval 
by the Food and Drug Administration (FDA) of ECP as the first selective immunotherapy for 
the treatment of cancer. ECP was introduced as a treatment of CTCL, but has later been 
applied on a variety of T cell mediated diseases, such as Graft-vs-Host Disease (GVHD)[7-9], 
transplant rejection[10-12] and selected autoimmune disease[13-15]. Since 1992, St. Olavs 
Hospital has been authorized as a national centre for ECP treatment in Norway, as a part of 
the Department of Nephrology, until the responsibility was transferred to the Department of 
Dermatology in 2005. The treatment procedure, however, is still being performed at the 
dialysis ward. 
 
The ECP procedure 
ECP is a medical therapy based on leucapheresis, followed by extracorporeal treatment of the 
leucocytes with 8-methoxypsoralen (8-MOP) and illumination with ultraviolet light A (UVA) 
before being reinfused into the patient (Fig. 2). 8-MOP is a DNA-intercalating drug and acts 
by binding covalently to DNA only when illuminated with UVA, which results in induction 
of apoptosis in the treated leucocytes[16]. A procedure much used is to perform ECP of the 
patient on two consecutive days, once or twice a month. However, according to the severity of 
the disease, it may be performed more frequently.  ECP is considered to be an extremely safe 
treatment and serious toxicity and complications such as catheter related infections are 
infrequent. In a multicenter study of ECP in patients with chronic GVHD, no serious adverse 
effects were reported that could be related to ECP. Additionally, there was no evidence that 
ECP induced a generalized immunosuppression, as the incidence of infections was the same 
as in the controls[9]. This is a great advantage especially in GVHD patients, in whom therapy 
with high doses of immunosuppressives would be the alternative. 
 
 Fig. 2 The ECP procedure (schematic). Whole blood is drawn from the patient (1), and cells separated from 
plasma in the photopheresis apparatus by centrifugation (2). Red cells and plasma are returned to the patient 
(3), while leukocytes (buffy coat) (4) are processed in the apparatus by mixing with 8-methoxypsoralen (5), 
which is then photoactivated by illumination with UVA-light (6) and returned to the patient (7) in a closed 
circuit. 
 
Graft vs Host Disease 
GVHD is a condition that evolves when immunocompetent cells, especially T cells, are 
introduced into an immunoincompetent host, and was first described by Billingham in 1959 
[17]. The main cause is haematopoietic cell transplant (HCT), but solid organ transplants[18] 
and blood transfusions[19] are also reported to cause GVHD. The acute form of GVHD arises 
within the first 3 months after transplant, and clinically presents with the triad: dermatitis, 
enteritis and hepatitis[20]. The chronic variant of GVHD often presents more like a lichen 
planus-like eruption or as scleroderma, by definition more than 3 months after transplant. The 
chronic form may occur either as a continuation of acute GVHD, or as a distinct entity[21]. 
 
In chronic GVHD, the skin is often the first organ affected, and the patients may present with 
erythematous macules and papules. This may resemble several other similar skin conditions 
that also occur after transplantations, such as viral exanthemas, drug eruptions and 
engraftment syndrome, as well as more benign dermatitis, making the diagnosis difficult[22]. 
In spite of immunosuppressive treatment before, during and after transplant, GVHD is still the 
leading cause of morbidity and mortality after HCT[20, 21]. 
 
__________________________________________________________________________________________ 
Doctoral Thesis  Vidar Rao – 2009 
Faculty of Medicine, NTNU 
13
__________________________________________________________________________________________ 
Doctoral Thesis  Vidar Rao – 2009 
Faculty of Medicine, NTNU 
14
The pathophysiology of GVHD is the recognition of target tissues as being foreign, with a 
subsequent induction of an inflammatory response, leading to death of the targeted tissue. 
Regulatory CD4+CD25+Foxp3+ T cells are reported to protect against chronic cutaneous 
GVHD[23]. 
 
The best treatment for GVHD is prophylaxis, and usually consists of immunosuppressive 
drugs, such as methotrexate, prednisone, cyclosporine etc. Once the diagnosis is made, the 
treatment consists of increasing the immunosuppressive agent, and possibly adding other 
modifying agents[24]. Immunomodulation by phototherapeutic agents has been proven 
beneficial for some patients, especially with chronic GVHD. PUVA is most widely used, but 
success has also been reported with ECP[9, 25], which is thought to trigger certain tolerance 
mechanisms [26, 27].  
 
Cutaneous T cell lymphoma 
Primary cutaneous T cell lymphoma (CTCL) is a rare entity. It is subdivided and classified 
according to the WHO-EORTC 2005 classification [28], and Mycosis Fungoides (MF) is the 
most common subtype, accounting for about 75% of the CTCLs. The incidence varies across 
the world. In the US, the incidence of MF from 1973-1992 was 0,36 per 100.000 person years 
[29], whereas the incidence rate in Norway is somewhat lower [30].  
MF is an indolent type of lymphoma. The disease starts with patches, which after years or 
even decades develop into thin and thick plaques. In a minority of patients, the disease results 
eventually in tumours and in dissemination to lymph nodes, blood, bone marrow, and internal 
organs. Involvement of mucous membranes is an exception. The disease does not develop 
continuously, but instead shows a stepwise progression[31]. Sezary Syndrome (SS) is the 
erythrodermic, leukemic subtype of CTCL and accounts for only about 3%. This leukemic 
form of CTCL is defined by erythroderma, lymphadenopathy and the presence of neoplastic T 
cells (Sezary cells) in skin, lymph nodes and peripheral blood, whith an absolute Sezary cell 
count of at least 1000 cells/ml. Clinically, edema, hyperkeratosis of palms and soles, and 
therapy-resistant pruritus are typically present[31].   
 
 
 
 
 
Table 1. World Health Organization-European Organization for Research and Treatment of 
Cancer (WHO-EORTC) classification of cutaneous lymphomas with primary cutaneous 
manifestations. 
 
 
 
           
Fig. 3 Histological hallmark: Lymphocytes infiltrate the epidermis, and create the characteristic Pautrier’s 
micro-abscess (black arrows), which in these three examples are situated just below the stratum corneum in 
mycosis fungoides. Thanks to Dr. Harald Aarset (Dept. of Pathology, St. Olavs Hospital) for giving permission 
to use his illustrative  photos.  
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Histologically, in MF there is an infiltrate of CD30- T cells in the skin, and as they move 
throughout the epidermis they tend to create Pautrier’s micro-abscesses (Fig. 3), which are a 
hallmark of the disease. As the condition progress, cells with a large, cerebriform nucleus 
(Sezary cells) can be seen in a blood smear[31]. 
 
The treatment is usually palliative only. An exception is the early Stage Ia, where treatment is 
initiated with a curative intention. Early detection and aggressive intervention is not shown to 
cure nor delay the progression of the disease. The prognosis of MF is dependent on stage and 
extent of the skin lesions, as well as the presence of extracutaneous manifestations. Patients 
with limited patch/plaque stage has a 10-year survival similar to a matched control population 
(98-99%), compared to approx. 40% in the tumour stage, and 20% if there is confirmed 
lymph node involvement[32-34]. When it comes to palliative treatment, there are several 
possibilities[35]. In the early stages, local steroids may limit the symptoms, as well as 
narrowband ultra violet light-B (UVB), whereas later stages could respond to oral psoralen + 
total body UVA (PUVA) or local chemotherapy in the combination with interferon. In the 
tumour-stage, systemic chemotherapy or radiation therapy may ease the symptoms. ECP is 
usually performed on erythrodermic stages of MF and SS resistant to conventional treatment, 
and sometimes given in combination with interferon. The effect of ECP is, however, variable. 
Approximately one half of the patients with CTCL demonstrates a reduction in skin score by 
at least 50% within 12 months of treatment, and is categorized as responders to ECP[36]. 
Prognosis in CTCL is much related to clinical and histopathologic classification[32-34, 37], 
but criteria for predicting clinical response to ECP are mainly lacking. 
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In search of predictive markers 
The mechanism of therapeutic effect of ECP is still uncertain, but is likely to be explained by 
8-MOP binding covalently to DNA in circulating lymphocytes. This ultimately leads to cell 
proliferation arrest and induction of apoptosis in the treated cells[16]. In the case of CTCL, as 
the apoptotic cell debris is removed by DC which are then presenting tumour antigens on their 
surface, a tumour specific immune response against the lymphoma cells has been thought to 
occur. Based on this, one might expect to find circulating monoclonal T cells in peripheral 
blood of CTCL patients responding to this treatment, and stored patient samples were 
analyzed to retrospectively investigate the potential usefulness of determining T cell clonality 
as presented in Paper I. 
 
Interleukin-2 (IL-2) is a cytokine synthesized and secreted by activated T lymphocytes, and 
leads to proliferation of cells carrying the IL-2 receptor (IL-2R). When activated, T cells start 
shedding their IL-2Rα, which is then recovered in serum as a soluble form (sIL-2R). 
Activation and proliferation of T cells is thus reflected by increased serum levels of sIL-2R, 
an indirect measure of IL-2 production[38]. The sIL-2R is exploited to monitor several 
inflammatory, infectious and neoplastic diseases associated with B- or T cell activation. sIL-
2Rα can thus be measured in blood or other body fluids of both healthy and diseased 
individuals such as in viral infections and arthritis, as well as in lymphomas[39]. The level of 
lactate dehydrogenase (LD) is also used clinically as a prognostic factor to characterize the 
growth and invasive potential of tumors[40]. 
 
Neopterin is produced and secreted by activated monocytes, i.e. macrophages and DC, and is 
a sensitive marker for cellular immunity. The serum concentration is reported to be elevated 
in several T cell associated diseases, such as CTCL, transplant rejections and viral infections 
such as HIV[41]. Beta2-microglobulin (β2-M), which otherwise constitute the invariant β-
chain of the HLA class I molecules, are together with sIL-2R as well as LD reported to be of 
prognostic value in CTCL, as high serum levels correlate to a poor therapy response and 
prognosis[42-45]. 
 
Cytolytic T cells contain preformed granules containing enzymes. After binding of the 
cytolytic cell to a target cell, the granules are released into the intercellular space. The 
granules contain a pore-forming protein (perforin), allowing released exogenous serine 
proteases (granzymes) to enter the cytosol of the target cells through the transmembrane 
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pores. Granzyme B activates an intracellular cascade of caspases, finally resulting in  killing 
of the target cells[46]. Not all of the granzyme B will enter the cell, as some of it may leak out 
and enter the blood stream and thus be reflecting the cytolytic activity in vivo[37, 47]. 
 
In Paper I, we have reanalysed in stored samples the occurrence of T cell monoclonality in 
skin biopsies and peripheral blood of CTCL patients at the time of starting ECP treatment.   
We have also investigated the serum levels of sIL-2R, LD, neopterin, β2-M  and granzyme B 
in CTCL patients during the course of treatment. The intention was to look for factors 
correlating to the therapeutic effect of ECP and thus possibly be of value in predicting which 
patients who will benefit from ECP treatment and in monitoring disease activity during the 
therapy. 
                 
Apoptosis 
Apoptosis is a normal process in living organisms, and between 50 – 70 billion cells undergo 
apoptosis each day in the average human adult. The process of apoptosis was initially 
discovered for over 100 years ago, but described in detail by Kerr et al. in 1972 while he was 
studying tissues using electron microscopy at the University of Queensland in Brisbane. He 
had originally called it “programmed cell necrosis”[48]. He credited Prof. Cormack, a 
Professor in Greek, for suggesting the term “apoptosis”, which translates to “dropping of” 
petals or leaves from plants or trees. Hippocrates had used the term to mean “falling of the 
bones”, and Galen extended its meaning to “the dropping of the scabs”. The term ‘apoptosis’ 
is now synonymous with programmed cell death, and is an active, and controlled process 
requiring energy. This is in contrast to necrosis, which is a passive, degenerative process, 
caused by injury or compromised metabolism. Apoptosis, despite a variety of inductive 
signals, follows the same pathway and ultimately leads to fragmentation of cells into 
apoptotic bodies with a still intact plasma membrane. A cell undergoing apoptosis shows a 
characteristic morphology that can be observed with a microscope: Cell shrinkage and 
rounding due to the breakdown of the cytoskeleton. The cytoplasm appears dense, and the 
organelles appear tightly packed. Chromatin undergoes condensation into compact patches 
against the nuclear envelope in a process known as pyknosis, a hallmark of apoptosis. The 
nuclear envelope becomes discontinuous and the DNA inside it is fragmented in a process 
referred to as karyorrhexis. The nucleus breaks into several discrete chromatin bodies due to 
the degradation of DNA. The cell membrane shows irregular buds. The cell breaks apart into 
several vesicles called apoptotic bodies, which are then finally phagocytized by macrophages 
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or DC[49]. One of the many common events of apoptosis is the externalization onto the cell 
membrane of phosphatidylserine, which can be detected with flow cytometry, by the binding 
of Annexin V. 
 
What happens to monocytes and dendritic cells after ECP? 
8-MOP is a DNA-intercalating drug and acts by binding covalently to DNA only when 
illuminated with UVA, hence inducing apoptosis in the treated lymphocytes. 8-MOP alone, 
without UVA, has no apparent effect[50]. ECP is known to induce apoptosis in 
lymphocytes[16] whereas until recently a common opinion has been that the monocytes were 
mainly not rendered apoptotic, but rather activated to differentiate into immature dendritic 
cells (DC). This theory is however under debate[50-58]. After the ECP treatment, the 
apoptotic cells are phagocytized in vivo and peptide antigens from phagocytized cells are 
expected to be presented on class II HLA molecules and even on class I 
(transimmunization)[51]. The exact mechanisms explaining the clinical response to ECP has 
yet to be fully revealed.  
 
Ionizing radiation is another method to induce apoptosis of lymphocytes, but the effect on 
monocytes and immature DC is less known. However, even though being remarkably 
resistant to radiation-induced apoptosis, it has recently been suggested that irradiation may 
affect some of the functions of the DC, such as reduced IL-12 production and impaired T cell 
priming[59]. 
 
DC can be generated from blood monocytes during 5 days of  cultivation with the cytokines 
interleukin-4 (IL-4) and granulocyte/macrophage colony stimulating factor (GM-CSF)[60-
64]. Immature DC are specialized in internalizing and processing antigens, but rather 
ineffective as antigen presenting cells and in stimulating naïve T cells. Even though they do 
express both HLA class II and HLA class I, their expression of co-stimulatory molecules such 
as CD86, CD40 and CD80 is low. Surface expression of the mannose receptor (CD206) has 
been regarded a differentiation hallmark of monocyte-derived immature DC, in contrast to 
monocytes and mature DC[63, 65]. However, when the immature DC encounter inflammatory 
or infectious signals such as lipopolysaccharide (LPS) or tumor necrosis factor-α (TNF-α), 
they are capable of differentiating into a mature state. CD83 is a specific marker of mature 
DC, and in contrast to the immature DC, these mature cells are professional antigen 
presenting cells and effectively stimulate T cell responses[64, 66-68]. 
 In Paper II, we performed a study to elucidate some of the short-term effects of ECP 
treatment on monocytes and in vitro generated monocyte-derived immature DC. We also 
wanted to compare the effect of gamma irradiation as an alternative method to induce 
apoptosis of monocytes and DC. In addition we were interested in evaluating the post-
treatment differentiating capacity of the cells. 
 
 
Fig. 4 Generation of dendritic cells in vitro. Immature dendritic cells can be generated from CD14+ monocytes 
during 5 days of cultivation with the cytokines IL-4 and GM-CSF. When stimulated with lipopolysaccharide 
(LPS) they are capable of differentiating into a mature state 
 
CD4+ helper T cells: at a glance 
CD4+ T cells orchestrate the adaptive immune responses and play a central role in the body’s 
immune defence. For instance, they produce different cytokines and chemokines to recruit 
neutrophils, eosinophils and basophils to the site of inflammation. They activate B cells to 
produce antibodies. They induce differentiation of monocytes into macrophages, and activate 
them to enhance their microbicidal activity.  
Traditionally, immunologists have divided the CD4+ T cell population into two distinct 
subsets based on functional criteria and cytokine production. The inflammatory helper T cells 
1 (Th1), that mainly produce IFN-γ, and helper T cells 2 (Th2), that mainly produce IL-4 as 
their hallmark cytokine [69, 70]. Later, it has been discovered that this distinction was overly 
simplified, and at present there are several different subsets of interest. Some of the CD4+ T 
cell populations are distinguishable from the others already as they leave the thymus, such as 
the “natural” regulatory T cells (nTreg) [71] and natural killer T cells (NK T cells)[72]. 
However, at least 4 other subsets can be differentiated from naïve CD4+ T cells based on the 
signals they receive: Th1, Th2, Th17 and “induced” regulatory T cells (iTreg). 
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Identification and function of Th1, Th2 and Th17 cells 
Th1 cells have an important role in the immune defence against intracellular pathogens [73, 
74] such as viral and mycobacterial infections, by expanding the CD8+ cytolytic T cells. 
Dysfunction in the Th1 subset is also related to certain autoimmune diseases. IFN-γ, IL-2 and 
lymphotoxin-α are the main cytokines secreted. Th1 cells express several cytokine and 
chemokine receptors upon activation, such as IL-12Rβ, CXCR3 and CCR5 [75-77]. T-bet is 
considered to be the principal Th1 cell transcription factor. It is up-regulated during Th1 
differentiation, induce IFN-γ production and inhibit IL-4 secretion[78]. In addition, Stat4, an 
IL-12 signal transducer, is important in the amplification of Th1 responses[79, 80].  
 
Th2 cells, on the other hand, play a leading role in fighting extracellular parasites, as well as 
in the induction and persistence of different allergies and asthmatic disease[73, 74]. As 
mentioned previously, IL-4 is their hallmark cytokine. In addition, they produce IL-5, IL-9, 
IL-10, IL-13 and IL-25[81, 82]. Without going into detail, these cytokines may mediate the 
recruiting of eosinophils, expulsion of parasites, or induction of airway hypersensitivity. Th2 
cells may be identified, among other surface antigens, by their expression of the chemokine 
receptor CCR3[83]. When blocking the transcription factor GATA-3, development of and 
maintenance of Th2 cells is abrogated[84, 85].    
 
When it comes to the induction of many organ-specific autoimmune disorders, in addition to 
the immune response against extracellular bacteria and fungi, Th17 cells are thought to be  
responsible[86]. They produce the cytokines IL-17a, IL-17f, IL-21 and IL-22, which recruit 
and activate neutrophils, T cells, B cells, NK-cells and dendritic cells in the setting of an 
infection with fungi or extracellular microbes. Th17 cells may be identified by their high 
expression of IL-23R, as well as CCR6 and CCR4[87]. RORγτ and RORα have been proven 
to be important transcription factors for Th17 cell differentiation, as a deletion of both 
completely abolish IL-17 production[88, 89]. 
 
Regulatory T cells 
The idea of T cells with a suppressive character arose in the early 1970s, as T cells seemed 
necessary for the induction of B cell tolerance[90, 91]. Suppressor T cells, as these negative 
regulatory cells became known, were assumed to be a distinct cell population and were 
intensively investigated. In the 1980’s, investigators began to raise questions about the 
interpretation of the previous studies, and within short time the term “suppressor T cell” 
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almost disappeared. However, new studies suggest that there is in fact a subset of T cells 
having a critical function in the prevention of autoimmune disease. These T cells, named 
“regulatory T cells” (Treg), have now become a major focus of cellular immunological 
investigation, and constitute a subset of T cells with immunosuppressive properties[92]. As 
these cells are being further investigated in detail, additional classification has been required 
based on origin, phenotype and suppressive mechanism, creating a rather complex list of 
abbreviations and names: “natural” Treg (nTreg), “induced” CD4+ Treg (iTreg) and Tr1-cells, 
Th-3 cells (involved in mucosal tolerance in the gut) and CD8+ iTreg. 
 
Identifying discriminatory cell-surface markers for the characterization and isolation of Treg 
cells has been a crucial goal for some time. Treg cells were first identified as helper T cells 
(CD4+) that strongly expressed CD25 (IL2-Rα), both in mice and humans[93, 94]. In humans, 
however, it has been shown that activated T cells generally up-regulate CD25 expression[95], 
thus decreasing the purity of Treg cell isolation by this marker and limiting its utility when 
studying Treg cells. It is known that Treg cells express several other characteristic molecules 
in addition to being CD25high, such as glucocorticoid-induced tumour necrosis factor 
receptor (GITR), cytotoxic T-lymphocyte antigen 4 (CTLA4) and L-selectin (CD62L). The 
above mentioned cell-surface- or intracellular molecules are, unfortunately, also expressed in 
activated T cells, thus making an exclusive isolation of viable Treg cells a substantial 
problem. At present the transcription fator Forkhead box p3 (Foxp3) is considered the most 
specific marker for Treg cells. This protein is however intracellular and not available for 
isolation of living cells. The search for Treg specific cell-surface markers continues, and 
several candidates have recently been assessed[96]. The importance of Foxp3 was 
demonstrated by showing that Foxp3-mutant mice have a Treg cell-deficiency and develop a 
severe lymphoproliferative autoimmune syndrome[97]. Similarly, humans lacking Foxp3 
suffer from an aggressive autoimmune syndrome, known as immuno dysregulation, 
polyendocrinopathy and enteropathy, X-linked (IPEX) syndrome, a rare recessive disorder 
that results in early death[98]. When first discovered in mice, Foxp3 was thought to 
exclusively identify Treg cells also in humans, but recent evidence support that Foxp3 indeed 
can be induced upon T cell activation, and that these Foxp3+ effector T cells are without 
immunosuppressive properties. Hence, low expression of specific cell-surface markers should 
also be exploited to assess and identify Treg cells, for instance that they have low expression 
of CD127 (known as IL7-Rα), whereas activated, effector T cells are CD127high[99, 100]. 
Treg cells are thought to be capable of inhibiting immune responses against a variety of 
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antigens, including the ones expressed by malignant cells[101]. In preventing autoimmune 
disease, the presence of Treg cells is naturally thought to be beneficial, whereas in the context 
of CTCL high numbers of these regulatory cells have mainly been supposed to inhibit the 
surveillance and clearance of tumour cells. Indeed, investigators have suggested that there is 
an association between a high tumour burden or tumour progression and an increase in Treg 
cells[102]. CD103, an αEβ7 integrin that mediates T cell retention in the epithelial 
compartment, has been shown to be an excellent marker for identifying in vivo-activated 
(induced) Treg cells[103, 104]. These CD103+CD4+Foxp3+ Treg cells have been shown to 
be more potent suppressors in autoimmune arthritis[103] and in reversing chronic GVHD, 
than primary CD4+CD25high Treg cells[105]. CD39 is a member of the ectonucleoside 
triphosphate diphosphohydrolase family, and is expressed on the surface of various cells. Its 
function is to degrade ATP, which acts as a “danger signal” that activates the immune system, 
to AMP. In combination with CD73, another ectonucleotidase, it results in the production of 
adenosine, that exhibit inhibitory and antiproliferative effects. Recently, it has been shown 
that CD39 is confined to a subset of the Treg cells, thought to represent regulatory cells with 
effector/memory-like properties. In the same study, the expression of CD39 among the Treg 
cells was also reflected in the capacity to degrade ATP, as well as in suppressive 
capacity[106]. CD45RA is a surface marker of primary (naïve) T cells in contrast to 
secondary (antigen-stimulated) T cells. 
 
There are four basic mechanisms of how the Treg cells are thought to function as suppressors. 
The first mechanism involves suppression by secretion of inhibitory cytokines, especially 
Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β). The importance of 
these cytokines are, however, a matter of debate due to the general perception that Treg cells 
function in a contact-dependent manner[107, 108]. Interleukin-35 (IL-35) has also recently 
been reported to be a necessity to achieve maximal suppressive activity of Treg cells[109]. 
A second mechanism reported is suppression by cytolysis, through the secretion of 
granzymes, which ultimately induce cytolysis of effector T cells. This has long been thought 
to be the mechanism of action by natural killer cells and CD8+ cytotoxic T cells. However, 
there are publications that support that granzyme-deficient Treg cells have reduced 
suppressive activity[110]. 
A third mechanism of the immunosuppressive action of Treg cells, is a theory about 
suppression by metabolic disruption. For instance, that CD25+ Treg consume the Interleukin-
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2 (IL-2) available, and thus starves the effector T cells by consuming the IL-2 they need to 
survive[108, 111]. This theory is, however, under debate. 
Finally, suppression by targeting dendritic cells has been reported. By modulating the 
maturation and hence decreasing dendritic cell function, i.e. decreasing effector T cell 
activation[112]. It has also been shown that Treg cells induce down-regulation of the 
expression of the co-stimulatory molecules CD80 and CD86 in dendritic cells[113]. 
 
Paper III is a study performed to determine the relative numbers of Treg cells, characterized 
by the phenotype CD3+CD4+Foxp3+CD127-, prior to ECP and after 6 months of ECP 
treatment in patients with CTCL or GVHD. Further characterization was done to analyze the 
expression of CTLA4, CD25, CD45RA, CD103 and CD39 among the Foxp3+ cells. In 
addition we assessed whether there was any change towards a tolerogenic profile, by 
assessing the serum concentrations of IL-4, IL-6, IL-10, IL-17, IFN-γ and TGF-β, before and 
after 6 months of ECP treatment. 
 
 
 
Aims 
Paper I 
Since 1992, St. Olavs Hospital has been the only centre in Norway authorized to practice ECP 
treatment, and an evaluation of the therapy is essential to improve the management of the 
patients in need of ECP. During these years, lymphocytes and sera have been collected from 
patients at different intervals during treatment, and stored as frozen samples. 
While positive results of ECP have been reported in patients with graft vs. host disease[7] and 
in preventing graft rejection in heart and renal transplantation[10-12], the effect on CTCL is 
variable. Only about one half of the treated CTCL patients demonstrate sufficient reduction in 
disease severity to be classified as “responders” to ECP treatment[36]. Reliable predictive 
criteria for selecting patients who will respond to ECP are lacking, and such criteria would 
naturally be of great benefit. As described in the introduction part, the potential predictive 
criteria investigated in this study include T cell clonality and serum factors as: soluble 
interleukin-2 receptor (sIL-2R), lactate dehydrogenase (LD), neopterin, beta2-microglobulin 
(β2-M) and granzyme B. 
The serum values of the above mentioned parameters were measured pre-treatment, after 6 
months and 12 months of treatment. 
Paper I - Summary of aims: 
1. Evaluate the response rate to ECP in CTCL patients treated at St. Olavs 
Hospital. 
2. Retrospectively investigate the potential usefulness of determining: T cell 
clonality in periphereal blood, and sIL-2R, LD, neopterin, β2-M and granzyme B 
in patient sera as predictive markers for response to ECP.    
 
 
Paper II 
This part of the thesis is an attempt to elucidate the effects of ECP treatment on monocytes 
and dendritic cells. Strong evidence support the fact that extracorporeal photochemotherapy 
induces complete apoptosis in lymphocytes. However, until recently the opinion has been that 
monocytes are resistant to the exposure of 8-MOP and UVA-light in combination. Later 
studies have on the other hand suggested that also the monocytes become apoptotic by the 
treatment, but somewhat slower than the lymphocytes[50, 53, 58].    
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Berger et al. [51] reported that repeated adhering to the plastic membranes in the ECP system 
induces activation and differentiation of the monocytes into immature DC, by stimulating the 
cells to secrete IL-1, TNF-α and IL-6. Further on, they suggested that an over-night 
incubation step, before returning the treated cells to the patient will allow the DC to 
phagocytise apoptotic CTCL cells in high concentration. This would generate the time to 
process engulfed tumour cells and display tumour antigen on their HLA class I and class II, 
and finally improve the antigen presentation in vivo when reinfused. A prerequisite for this 
concept must be that the monocytes actually survive the ECP-treatment. If the monocytes 
survive the treatment they have to be able to differentiate into phagocytising immature DC, as 
well as stay viable long enough to reach the antigen presenting mature state. If this is the case, 
an incubation period before reinfusing the cells will probably increase the phagocytosis of 
apoptotic CTCL-cells and thus improve the following antigen presentation in vivo. 
On the other hand, knowing that the ECP treatment ultimately leads to incorporation of 8-
MOP in all treated cells and a covalent cross binding between double-stranded DNA, makes it 
somewhat hard to fully comprehend that the monocytes should remain unaffected by the 
treatment. Even if the monocytes are viable after treatment, their function and ability to 
differentiate may be reduced. Therefore, elucidating the effects of ECP treatment on 
monocytes will give information about the viability and capability to differentiate after 
treatment, as well as clarifying the importance of such an over-night incubation step. 
We also wanted for comparison to investigate the effects of gamma irradiation on monocytes 
and DC, as an alternate inductor of apoptosis. 
__________________________________________________________________________________________ 
Doctoral Thesis  Vidar Rao – 2009 
Faculty of Medicine, NTNU 
26
 
Paper II - Summary of aims: 
1. Elucidate the effect of ECP on monocytes, regarding induction of apoptosis and 
ability to differentiate into immature dendritic cells when stimulated with IL-4 and 
GM-CSF. 
2. Elucidate the effect of ECP on in vitro differentiated immature dendritic cells, 
regarding induction of apoptosis and ability to progress to mature dendritic cells 
when stimulated with lipopolysaccaride  
3. Use gamma irradiation as an alternative method of apoptosis induction, and follow 
the cells regarding induction of apoptosis and ability to differentiate. 
 
 
 
Paper III 
Regulatory T cells (Treg) have been reported to protect against chronic GVHD, and the effect 
is thought to be mediated through the triggering of certain tolerance mechanisms such as 
inhibition of pro-inflammatory cytokines, stimulation of Treg cells and production of anti-
inflammatory cytokines [23, 27]. A major problem with clinical ECP in CTCL is that we still 
do not know what effect we aim at obtaining. Due to the findings of monoclonal T cells in 
peripheral blood, one explanation has been that ECP induces an anti-clonotypic cytolytic 
immunity directly against the tumour cells[56]. An essential issue in CTCL is whether ECP is 
inducing specific cytotoxicity against the lymphoma cells, or alternatively inducing specific 
or non-specific Treg cells controlling the CTCL proliferation. The success obtained with 
priming dendritic cells in cancer therapy could point to the first possibility [114, 115], 
whereas the effect of ECP in GVHD, transplant rejection and autoimmunity favours the other 
view [7, 10-14]. 
This study was performed to determine the relative numbers of Treg cells, characterized by 
the phenotype CD3+CD4+Foxp3+CD127-, prior to ECP and after 6 months of ECP treatment 
in patients with CTCL or GVHD. Further characterization was done to analyze the expression 
of CTLA4, CD25, CD45RA, CD103 and CD39 among the Foxp3+ cells. In addition, we have 
assessed whether there is any change in a representative serum cytokine profile of helper T 
effector cells and Treg cells among these patient groups during ECP, by assessing the serum 
concentrations of IL-4, IL-6, IL-10, IL-17, IFN-γ and TGF-β, during 6 months of ECP 
treatment. 
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Paper III - Summary of aims: 
1. Compare the relative fraction of regulatory T-cells among healthy controls, 
patients with CTCL and patients with GVHD. 
2. Investigate whether there is a change in the relative fraction of regulatory T cells 
in CTCL or GVHD patients during 6 months of ECP treatment.  
3. Study if there are any differences in the relative fraction of regulatory T cells 
between CTCL patients responding to treatment, compared to the non-responders. 
4. Investigate whether there is a measurable change in serum concentrations of IL-4, 
IL-6, IL-10, IL-17, IFN-γ or TGF-β after 6 months of ECP treatment. 
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General Material and Methods 
(See enclosed publications for details) 
 
 
Study populations 
In Paper I, Serum and peripheral blood mononuclear cells (PBMC) from 16 CTCL patients, 
diagnosed with MF or SS and treated with ECP, between 1993 and 2003, were evaluated in an 
open, retrospective study. The clinical manifestations of the patients were heterogeneous and 
are summarized in Table 1 (Paper I). The CTCL patients were classified at initiation of ECP 
according to a skin score test defined as the product of skin disease severity score multiplied 
by percent affected body surface area[6]. The skin disease severity score is according to the 
following scale: 0 = normal, 1 = barely detectable erythema and scaling, 2 = readily 
detectable erythema, edema and scaling, 3 = marked erythema and exfoliation, and 4 = 
fissuring, maximal erythema, induration and tumors. This makes 400 (4 x 100%) the maximal 
total skin score. The clinical response of the CTCL patients to ECP was defined as a reduction 
in skin score by at least 50% as registered after 12 months of ECP treatment. Skin biopsies 
were taken of all patients, and peripheral blood was examined for atypical cells. Lymph node 
biopsies were performed on all patients with palpable lymphadenopathy. X-ray or CT-scan of 
the chest, as well as ultrasound or CT-scan of the abdomen was performed to evaluate clinical 
stage. For this retrospective study, blood samples were obtained immediately before the first 
ECP procedure, after a 6 months course of therapy and 12 months after initiating therapy 
when the clinical effect of ECP was assessed. Sera were stored at -70ºC and PBMC in 10% 
DMSO at −135°C. 
In Paper II, PBMC were isolated from healthy blood donor buffycoats using Lymphoprep 
(Axis-Shield, Oslo, Norway). Monocytes were then positively extracted by immunomagnetic 
sorting, using magnetic anti-CD14-MicroBeads and MACS separation columns (Miltenyi 
Biotec, Bergisch Gladbach, Germany), and cultivated after treatment with in vitro ECP or 
gamma irradiation. 
In Paper III, stored serum and PBMC from a total 58 individuals were evaluated. This study 
population included patients with CTCL (n=24) or GVHD (n=14) treated with ECP between 
1993 and 2008, as well as controls obtained from healthy blood donors (HC, n=20). The 
CTCL and GVHD patients were evaluated pre treatment, and after 6 months of ECP 
treatment. See Table 1 and 2 (Paper III) for individual data on CTCL and GVHD patients, 
respectively. 
 
Evaluation of T cell clonality in skin biopsies and peripheral blood by TCRγ chain PCR 
To get a uniform and qualified re-evaluation of occurrence of monoclonal T cells, DNA was 
extracted from stored paraffin-embedded skin biopsies and from peripheral blood 
mononuclear cells stored at –135oC. The DNA was quantified by fluorometry. Specific 
consensus primers were used for each family of the variable (V) and joining (J) regions of the 
TCRγ gene. The primers used were based on those described by Vega et al[116]. Two parallel 
PCR reactions were performed using DNA in two different dilution folds. PCR amplification 
was performed in a thermal cycler (GeneAmp PCR system 2700). Following the PCR 
reactions, the samples were loaded on a DNA sequence analyser (ABI 3100, Applied 
Biosystems). Fluorescence data were analysed using GeneScan software. The presence of 
monoclonality was determined by the presence of 1 or 2 peaks. DNA isolated from T 
lymphoma cell line Jurkat was used as positive control for both primer sets. The presence of T 
cell monoclonality in peripheral blood was valid when an identical fluorescence peak 
emerged for a corresponding skin biopsy sample of the same patient. 
 
Fig. 5 TCR clonality. An example of how the presence of T cell reseptor γ chain (TCRγ) clonality in peripheral 
blood was assessed. After PCR, the samples were loaded on a DNA sequence analyzer, and the fluorescence 
data from the PCR product were analyzed using GeneScan Software. The blue peaks represent the distribution of 
the TCRγ chain in a polyclonal (A) and a monoclonal (B) sample. The red peaks represent a known scale or 
“ruler”. 
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Flow cytometry 
Cells were assessed freshly drawn, directly from cell cultures or after storage at - 135°C, and 
stained according to manufacturer’s instructions. Briefly, the cells were first stained for 
surface antigens, before permeabilized and stained for intracellular antigens when required. 
Flow cytometric analysis was performed using a FACScan™ or FACSCanto™ instrument 
(both obtained from Becton Dickinson Biosciences, San Jose, CA, USA). The FACScan™ 
cytometer is capable of detecting antibodies in 3-color combinations, whereas samples 
processed with the FACSCanto™ instrument were stained in 5- or 6-color combinations. See 
individual papers for further details. 
 
ELISA 
As described in Paper I, the soluble IL-2R, Granzyme B and neopterin enzyme-linked 
immunosorbent assay kits were obtained respectively from Immunotech (Marseille, France), 
Sanquin Reagents (Amsterdam, The Netherlands) and BRAHMS (Hennigsdorf, Germany). 
The tests were performed as recommended by the instruction manuals, and the results 
presented as mean of duplicates. 
  
Serum lactate dehydrogenase (LD) and beta2-microglobulin (β2-M) were analysed at the 
Hospital Department of Medical Biochemistry. LD was analysed by an enzyme assay (Roche, 
Basel, Switzerland) and performed according to standard procedures. β2-M was analyzed by 
radio immunoassay (RIA) techniques (B2-micro RIA 100, Pharmacia Diagnostics AB, 
Uppsala, Sweden). 
 
Cytokine assays 
In Paper III, serum stored at -70ºC, obtained pre-treatment and after 6 months of ECP 
treatment, was thawed and the concentrations of IL-4, IL-6, IL-10, IL-17 and IFN-γ were 
measured in duplicates, using a Milliplex Human Cytokine/Chemokine Immunoassay 
(Millipore Corporation, Billerica, MA, USA). The concentration of TGF-β was measured, 
also in duplicates, using a LINCOplex TGF-β1Single Plex Kit (LINCO Research, St. Charles, 
MO, USA). Both kits were applied according to the manufacturer’s instructions. Data were 
then collected on a Luminex 100 IS analyzer using the provided software (Luminex Corp., 
Austin, TX, USA). 
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In vitro ECP of monocytes and dendritic cells 
As described in detail in Paper II, monocytes were positively extracted by immunomagnetic 
sorting using anti-CD14-MicroBeads and MACS separation columns (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Either CD14+ monocytes immediately after immunomagnetic 
extraction (extracted CD14+ cells were >90% pure as measured with flow cytometry), or 
monocyte-derived immature DC after 5 days in culture with GM-CSF and IL-4, were 
incubated with 200 ng/mL 8-methoxypsoralen (8-MOP) for 15 minutes on ice in the dark. 
Subsequently the cells were exposed to 2 J/cm2 UVA-light using the Intercept illuminator 
(Cerus Corporation, Concorde, CA, USA) to simulate extracorporeal photochemotherapy 
(ECP). 
 
Alternatively, gamma irradiation was provided at doses of 30Gy or 90Gy while keeping cells 
on ice (137Cs, Sorø, Denmark). 
 
Immediately after treatment, the cells were cultured at 37 °C and 5% CO2 in 6-well flat-
bottom culture plates at a density of 1x106 cells/mL in a total of 3mL RPMI 1640 medium 
w/glutamine, supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 ug/mL of 
streptomycin, 80 ng/mL each of IL-4 and GM-CSF (R&D Systems Europe, UK). To induce 
maturation of the immature DC into mature DC, 10 ng/mL lipopolysaccharide (LPS) (Sigma-
Aldrich, St. Louis, MO, USA) was added on day 5 of culture. 
 
Apoptosis was evaluated with flow cytometry, by measurement of staining with annexin V 
and propidium iodide (PI) with a commercially available kit (IQProducts, Groningen, The 
Netherlands). Annexin V binds to phosphatidylserine, and externalization of 
phosphatidylserine is an early sign of apoptosis. Hence, cells stained with annexin V were 
classified as ‘apoptotic’. Annexin V-/PI- cells were classified as ‘viable’, i.e. non-apoptotic. 
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Main results and summary of papers 
 
Paper I 
Reliable predictive criteria for selecting CTCL patients who will respond to ECP are mainly 
lacking, and such criteria would naturally be of great benefit. In the first paper, we wanted to 
evaluate the response rate in 16 patients with CTCL treated with ECP, as well as to assess a 
selection of parameters retrospectively to investigate their potential usefulness as predictive 
markers. The occurrence of T cell clonality in skin biopsies and peripheral blood samples 
obtained before initiating ECP are presented in Table 1 (Paper I). Twelve of the patients 
(75%) in this study had T cell monoclonality detected in their skin biopsies by using PCR and 
DNA fragment analysis. Three of the four patients who did not have monoclonal T cells 
detected in their skin biopsies were patients included in the study as “suspicious of” MF, and 
diagnosed as Red Man Syndrome (RM). Clinically, the fourth patient was histologically 
diagnosed as MF, but without any T cell clone being detected in skin or blood. Eleven 
patients were found to have monoclonal T cells in peripheral blood, and among these the four 
patients diagnosed with MF in the responding group all had a detectable clone in both skin 
and blood. There were, however, no significant differences in distribution of these patients 
into the ECP responding and non-responding groups. The non-responding patient group on 
average had higher pre-treatment values of serum sIL-2R compared to the responding group, 
but this was not statistically significant. However, after 6 as well as 12 months of ECP 
treatment the difference in average serum sIL-2R between the two patient groups was 
significant (Fig. 1, Paper I). An individual reduction in serum sIL-2R concentration was well 
correlated to clinical remission measured as a reduction in skin score during 6 months of 
treatment. 
In conclusion, seven out of 16 patients were classified as responders to ECP. Neither T cell 
clonality nor any of the other serum markers assessed pre-treatment could reliably predict the 
response to ECP treatment. However, the individual relative changes in sIL-2R, neopterin and 
β2-M during 6 months of ECP treatment coherently displayed correlation to the clinical 
response, as assessed after 12 months of treatment. 
 
Paper II 
In Paper II, we wanted to elucidate the effects of ECP treatment on monocytes and dendritic 
cells (DC). Strong evidence support the fact that extracorporeal photochemotherapy induces 
complete apoptosis in lymphocytes. However, until recently the opinion had mainly been that 
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monocytes are resistant to the exposure of 8-MOP and UVA-light in combination, and rather 
differentiate into antigen presenting DC. In this study, we investigated the effect of ECP and 
gamma irradiation on lymphocytes, monocytes and immature DC in vitro, and followed the 
ability of the cells to differentiate and survive post treatment. We found that ECP induced 
apoptosis in all treated cells within 72 hours following treatment. This was in contrast to cells 
treated with 30Gy gamma irradiation, which seemed mainly to kill the lymphocytes. The 
small fraction of surviving ECP treated monocytes presented a reduced ability to differentiate 
into immature DC within this time frame. We also demonstrated that the few surviving 
immature DC lost their normal ability to mature on stimulation with lipopolysaccharide after 
ECP treatment. 30Gy gamma irradiation did not seem to hamper the monocytes’ ability to 
differentiate or the immature DC ability to mature. Monocytes and immature DC treated with 
2J/cm2 of UVA without incubation with 8-MOP or 8-MOP without UVA did not differ from 
the untreated control cells (not shown). 
In conclusion, as both monocytes and immature DC seemed to be doomed by the ECP 
treatment, it was suggested that the therapeutic effect of ECP is caused by in vivo effects of 
reinfused apoptotic cells, rather than by infusion of monocytes induced to differentiate into 
functional immature DC. 
 
Paper III 
In GVHD, the effect of ECP is reported to be mediated through induction of certain tolerance 
mechanisms, such as regulatory T cell (Treg) stimulation. In the case of CTCL an essential 
issue in explaining the mechanism of effect of ECP treatment, is whether ECP is inducing 
specific cytotoxisity against lymphoma cells, or alternatively, specific or non-specific Treg 
cells controlling CTCL proliferation. We included 24 patients with CTCL and 14 patients 
with GVHD to assess the relative fraction of Treg cells during 6 months of ECP treatment, 
compared to data obtained from 20 healthy controls. Individual data on CTCL and GVHD 
patients are presented in Table 2 and 3 (Paper III), respectively. In addition we studied 
whether there was a measurable change in a representative cytokine profile of effector T cells 
and Treg cells, by assessing the serum concentrations of 6 cytokines, IL-4, IL-6, IL-10, IL-17, 
IFN-γ and TGF-β, during the same treatment interval. We found that the mean relative 
amount of Treg cells was twice as high in the CTCL patients, compared to both the patients 
with GVHD and the healthy controls. Pre-treatment, the anti-inflammatory cytokine TGF-β 
was on average 3 times higher in GVHD than in CTCL. Both CTCL and GVHD patients had 
a small, but significant increase of TGF-β after 6 months of ECP treatment. There was also a 
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significant decrease of the inflammatory cytokine IL-17 in the GVHD patients. No differences 
were found among the other cytokines assessed. 
In conclusion, our results may indicate a strengthened Treg cell function in both patient 
groups as a result of ECP. Elevated TGF-β may indicate high Treg cell activation in GVHD, 
whereas an increased number of Treg cells in CTCL could be interpreted as a response that 
possibly is involved in down-regulating the lymphoma cells. 
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Discussion 
In search of predictive markers 
Based on cutaneous symptoms, histological examination of skin biopsies and detection of T 
cell monoclonality in skin and peripheral blood, patients were selected for ECP therapy and 
later included in the study presented in Paper I. A re-classification was done after a 
retrospective evaluation of the T cell monoclonality in skin biopsies and peripheral blood. 
Three patients were then classified as “suspicious of MF”, but still chosen to enter the study 
as Red Man Syndrome (RM), since they had accomplished the ECP therapy. Classification of 
the patients into responders and non-responders was based on the change in skin score and 
performed 12 months after initiation of the ECP. Based on the given criteria and including the 
RM patients, seven patients were classified as responders to ECP. Nine patients were 
classified as non-responders. This gives a response rate of 44% (7/16 patients) and is 
somewhat lower than the observations made by other investigators[36]. Further on, if 
excluding the RM patients, the response rate is even lower in this material (4/13 patients, 
31%). This may however be incidental due to the small size of the patient material. 
 
As presented in Table 1, Paper I, T cell clonality was detected in most patients both in the 
responding as well as the non-responding group. Detection of T cell clonality in skin or 
peripheral blood is important in assessing a diagnosis of CTCL, but in this evaluation, 
circulating clonal T cells does not seem to be a decisive factor in trying to predict the effect of 
ECP therapy. However, the exact physiologic effect of ECP is still not fully understood. 
Treatment with UVA and psoralen has in some publications been shown to induce apoptosis 
in the circulating malignant and non-malignant T cells, but not in monocytes[50, 58, 117]. 
ECP activation of dendritic cells that is leading to increased phagocytosis and antigen 
presentation of apoptotic cells has been demonstrated. ECP has been shown to increase MHC 
I surface antigen expression on CD4+ T cells, facilitating a cytolytic T cell response 
specifically against the pathogenic CD4+ T cells[54]. However, other mechanisms besides 
direct killing of malignant T cells have also been investigated. The phagocytosis of lymphoma 
cells has been supposed to result in production of specific suppressor T cells acting against 
clonal T cells[52, 55-58]. On the other hand, Berger et al. have proposed that CTCL may be a 
malignant proliferation of regulatory T cells (Treg), i.e. cells expressing a regulatory 
phenotype (CD25+, CTLA4+, Foxp3+), being stimulated by dendritic cells loaded with 
apoptotic CTCL-cells. These CTCL-Treg cells also secreted IL-10 and TGF-β, both cytokines 
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that will maintain dendritic cells immature and ensure continued phagocytosis and antigen 
presentation, inducing further CTCL-cell proliferation. That CTCL cells adopt Treg cell 
functions may explain the immunosuppressive effect seen in progressive CTCL disease[118]. 
However, Gjerdrum et al demonstrated that in skin biopsies the degree of Treg cell infiltration 
in CTCL was correlated to patient survival, and suggested that Treg cells can directly 
suppress the function of malignant T cells[119]. We think that their findings also contradict 
that CTCL cells have a Treg phenotype, as infiltrating lymphoma cells should clearly not 
correlate positively to patient survival. In addition, a report from  Tiemessen et al suggested 
that Treg cells in late stage CTCL are dysfunctional[120], which may explain the lack of 
tumour control seen in progressive disease. 
The presence of a T cell clone in blood anyhow would seem to be essential for obtaining 
response to ECP.  T cell receptor PCR and DNA fragment analysis is probably sufficiently 
sensitive for detecting clonality. However, in this study two patients classified as RM have 
responded well to ECP in spite that no clone was detectable in peripheral blood. Other 
essential prerequisites for activating an effective immune reaction are not so easily detected. 
The individual HLA constitution might be one factor of importance in relation to presentation 
of relevant antigens from the monoclonal cells. In any case an apparent therapeutic effect or 
not will be the result of a balance between an anti CTCL immune reaction and the 
proliferating capacity of the T cell lymphoma. A high tumor burden is likely to be 
unfavorable. Other mechanisms that might seem to be less dependent on the occurrence of 
circulating clonal T cells have been proposed. Some researchers have suggested that CTCL is 
a malignant proliferation of helper T cells type 2 (Th2). ECP appears to increase the helper T 
cells type 1 (Th1), and consequently to reverse the abnormally high Th2-cell level[121-123]. 
ECP has also been shown to induce the release of pro-inflammatory cytokines like TNF-α, IL-
1 and IL-6, which implicates monocyte activation[124, 125].  
It has been published by other investigators that increased serum levels of sIL-2R, β2-M as 
well as LD indicate an unfavorable response to ECP[42-45]. Our results indicate that non-
responders to ECP on average do have a higher pre-treatment serum level of sIL-2R than 
responders do. The difference is small and statistically insignificant, however, and thus not 
useful in predicting whether a CTCL patient will be a responder to ECP or not. Contrary to 
this we think that individual regress in serum sIL-2R level at 6 months of ECP is 
characterising responding patients and that this parameter can contribute to identify patients 
who can possibly benefit from further ECP treatment, either directly or at later relapse. In this 
material, we observed that the individual relative changes in serum concentrations of 
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neopterin and β2-M during 6 months of ECP were coherently correlated to the change in 
clinical disease, i.e. skin score. Both factors are indicators of immune activation. We found in 
this material only slightly elevated mean values of LD and indeed the responding group was 
the higher one. The difference is not statistically significant however and may be just 
incidental or because the age of the responders was on average 10 years higher than the age of 
the non-responders. Monitoring of granzyme B levels in serum does not seem to be of general 
interest in following up ECP of CTCL patients. We had hoped it could be used to reveal an 
ongoing cytolytic reaction against a T cell lymphoma, being released from activated 
responsive CD8+ cells. However, the test can probably be used to monitor tumor burden in 
the minority of CTCLs that are of cytolytic T cell (CD8+) origin. According to the one case 
reported in Paper I, the test does not seem to be very sensitive for this purpose, as granzyme B 
in serum was not detected before the CD8+ clone had reached 8% of circulating leukocytes, 
and it was not detected at the points of time when T cell monoclonality in skin and peripheral 
blood was first detected. 
 
In evaluating this rather small patient group of CTCL, we have not been able to identify any 
pre-treatment factor that can predict the clinical response of ECP. A reduction in serum sIL-
2R, neopterin and β2-M during the first course of ECP can however, add in the prediction of a 
better prognosis on the long run. Even if being a relative insensitive test granzyme B in serum 
can probably be used in monitoring the progress of cytolytic CD8+ T cell lymphomas. 
However, it should be assessed in combination with other markers such as skin score, skin 
biopsy, CD4/CD8-ratio and Sezary cell-count, when trying to assess disease severity, therapy 
and prognosis. 
Differences in results between the study presented in Paper I and studies made by other 
investigators may be due to the complexity of CTCL and thus of the patients included in 
different studies. This also means variation in duration of the disease, in treatment given 
before ECP and in intensity and duration of the ECP course. Most therapeutic centres have 
limited number of patients referred for ECP. Patient survival would be a stronger parameter to 
follow up than clinical response measured as skin score improvement. So far, the patients 
described here are too few for such a follow-up study.  
 
ECP induces apoptosis in monocytes and dendritic cells 
As expected, UVA-light (2J/cm2) without incubation with 8-MOP or 8-MOP without 
illumination with UVA did neither induce apoptosis nor affect the cells ability to differentiate. 
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However, when using 8-MOP and UVA in combination, we confirmed in our in vitro 
experiments presented in Paper II the previous observations that ECP made lymphocytes 
undergo apoptosis[50, 58, 126], and that this took place at the same kinetic rate as in gamma-
irradiated lymphocytes. The opinion on what happens to monocytes and DC after ECP has, 
however, been a matter of debate. In contrast to some previous reports, we observed that also 
the majority of monocytes underwent apoptotic cell death during the first 24 hours post-
treatment[52, 58, 127]. A limited number of investigators have followed the effect of ECP on 
monocytes for more than 24 hours post treatment. It has recently been reported, like in our 
investigation, that also monocytes turn apoptotic after ECP[53, 128-130]. Any discrepancies 
on this topic may partly be due to the methodology chosen for revealing apoptosis. For 
detecting early apoptosis we think that the use of annexin V is a favorable method[131, 132]. 
It has also been reported that DC harvested from peripheral blood of GVHD patients survive 
ECP[133]. We observed that monocyte-derived immature DC as well as DC harvested from 
peripheral blood underwent apoptosis as a result of ECP, the kinetics of which was much like 
that observed for lymphocytes. These observations led us to the conclusion that within 72 
hours post-treatment almost all ECP treated cells become apoptotic, the majority even earlier. 
The few DC surviving ECP showed a reduced ability to mature when stimulated with LPS.  
 
Somewhat surprisingly, monocytes seem to tolerate 30Gy of gamma irradiation without 
reduced viability and without losing their ability to differentiate into immature DC. When 
stimulating these cells in a next step with LPS for 72 hours, they gained the phenotype of 
mature DC. As a follow-up, both monocytes and immature DC were exposed to doses as high 
as 90Gy, and even though this resulted in a slightly increased fraction of apoptotic cells 
compared to 30Gy, it was still to a lesser extent than apoptosis induced by ECP (data not 
presented). In coherence with our findings, Merrick et al reported in 2005 that monocyte-
derived immature DC indeed do tolerate doses of gamma irradiation that induce apoptosis in 
lymphocytes, and they seem to maintain their differentiating, phagocytic and migratory 
capability to the same extent as untreated cells. However, an impact on their function was 
shown, as the irradiated DC produced less IL-12, and were less effective in priming naïve T 
cells compared to untreated control cells[59].  
 
The main objective of the present investigation was to elucidate the primary ex vivo effect of 
ECP on monocytes and DC, in an attempt to partly clarify this basic issue, before trying to 
disclose the main principal mechanism behind the clinical in vivo effect of ECP. Monocytes 
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are blood cells thought to have few other functions than being precursors to phagocytes, such 
as macrophages and DC, and it seems to be essential that they go through such a 
differentiation in order to function as antigen-presenting cells. Immature DC are specialized to 
phagocytize, and when maturing they get increasing capacity to present antigens on HLA 
class II and I, and being able to stimulate a primary immune response[64, 66, 67]. We 
demonstrated in this study that ECP treatment reduced the ability of surviving monocytes to 
differentiate into immature DC when cultured with IL-4 and GM-CSF, compared to untreated 
control cells. 24 hours post treatment, the control cells and the gamma-irradiated cells, in 
contrast to the ECP-treated cells, acquired the CD206 antigen, which is characterizing 
immature DC. From our series of experiments we observed that the differentiation from 
CD14+/CD206- monocytes to immature CD14-/CD206+ DC in response to IL-4 and GM-
CSF stimulation took 5 days. 
 
How functional are ECP treated monocytes and DC as antigen-presenting cells after 
reinfusion to the patient? This is a central question to follow a theory that recently has been 
presented as “transimmunization”, suggesting that clinical ECP would be more effective if 
including an overnight incubation step of the treated cells before returning the cells to the 
patient[51, 134]. This would, in theory, give the monocytes time to differentiate into 
immature DC which again can phagocytize the apoptotic lymphocytes at a high concentration, 
and thus, following reinfusion increase the efficiency of in vivo antigen presentation. 
However, our series of experiments indicated that when the ECP treated cells are incubated 
overnight, they should not be expected to differentiate into phagocytes, but rather to undergo 
apoptotic cell death. Maeda et al[129] very convincingly demonstrated in a mouse in vivo 
experiment by use of a dinitrofluorobenzene hapten antigenic system that ECP treated DC are 
indeed able to induce CD4+CD25+ antigen-specific regulatory T cells. Their applied DC had 
however, been exposed to the antigen in vivo for 5 days before submitted to ex vivo ECP and 
subsequently adoptively transfused to a second animal for tolerance induction. In their model 
the DC might have had a ‘flying’ start and hence time to exert their tolerizing effect before 
dying. In traditional clinical ECP, as well as in the proposed transimmunization model, the ex 
vivo treated monocytes/DC will primarily be induced to apoptosis, and they will not start their 
supposed antigen processing before the lymphocytes are dying. Our findings also indicated 
that a one-step procedure based on 30Gy gamma-irradiated cells instead of ECP-treated cells 
ought to be tried when testing out the transimmunization model as proposed by Berger et 
al[51], based on that monocytes/DC, contrary to lymphocytes, retained their viability and 
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differentiating potential following 30Gy gamma irradiation. This could give information 
about the effect of viable monocytes/DC in a procedure similar to ECP. The potential 
oncogenic risk of reinfusing viable gamma-irradiated cells is probably negligible, but should 
be evaluated before performing such a study. 
 
With traditional clinical ECP, a major problem is that we still do not really know which kind 
of an effect we aim at obtaining. One explanation has been that ECP induces an 
anticlonotypic cytolytic immunity directly against tumor cells, due to the findings of 
monoclonal T cells in the peripheral blood of patients with CTCL[56]. However, response has 
also been observed in CTCL patients lacking such a clone[135]. In CTCL, we do not know 
whether ECP is inducing specific cytotoxicity to the lymphoma cells or alternatively is 
inducing specific or non-specific regulatory T cells controlling the CTCL proliferation. The 
success obtained with priming DC in cancer therapy could point to the first possibility[114, 
115], whereas the effect of ECP in GvHD, transplant rejection and autoimmunity favor the 
other view[7-15]. Several potential mechanisms of action in GvHD has recently been 
reviewed, including production or inhibition of cytokines, inhibition of activated T cells or 
induction of regulatory T cells[27]. There are many issues that have to be addressed before a 
fully rational exploitation of ECP can be obtained. Which maturity state of the DC and which 
potential accessory stimuli should preferably be applied? We do not know the importance of 
what can be obtained by ex vivo phagocytosis compared to what takes place when reinfused 
apoptotic cells end up in the specialized phagocytic compartments of liver and spleen.  
 
Regulatory T cells and ECP 
Even if rarely curative, ECP can give clinical improvement to both CTCL and GVHD, two 
conditions that are pathogenetically very different, but have in common that they are very 
resistant to conventional therapeutic regimens. In the case of GVHD it may seem easy to 
understand the supposed effector-mechanism of ECP. This disease is mainly mediated by 
allogeneic effector T cells recognizing the transplant recipient as foreign, and with skin, 
intestine and liver as main target organs for an immunological attack. It is understandable that 
a therapy that can improve the Treg function can down-regulate the immunological attack and 
bring clinical alleviation to the patient, and that this may be the probable effect of ECP. When 
it comes to CTCL this issue is still not solved. What is the biology of Treg cells in this 
condition, and what is the effective mechanism mediated by ECP? The explanation that could 
seem to be the most likely possibility is that ECP strengthen a T cell cytolytic effect on the 
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CTCL analogous to what can be obtained by immunotherapy of solid tumours[115]. It seems 
paradoxical however, that ECP should improve a T cell regulatory function in one kind of 
patients and a cytolytic one in another. This is further complicated by the findings of Berger et 
al that the CTCL cells can by stimulation convert into a Treg phenotype[118], and Tiemessen 
et al have demonstrated that Treg cells in late stage CTCL are dysfunctional[120]. The 
potential mechanisms of immune regulation with ECP, which imply infusion of  apoptotic 
dying cells, have recently been reviewed[27]. In addition to stimulation of Treg cells, 
inhibition of pro-inflammatory cytokines, such as IL-1, IL-6 and TNF-α, as well as production 
of anti-inflammatory cytokines, such as TGF-β and IL-10, has been reported[136-139]. The 
appropriate concentrations of these cytokines may regulate the immune response at 
inflammatory sites.  
 
The study presented in Paper III was designed to make a comparison between two patient 
groups; CTCL and GVHD submitted to the same kind of ECP therapy during a parallel time 
course of some years. We chose to test freeze-stored serum and PBMC samples collected at 
start and ending of the standard 6 months course of ECP. The serums were tested for a 
cytokine profile representing the three kinds of T helper effector cells; Th1, Th2 and Th17, as 
well as Treg cells. As will be seen from Fig. 2 and Fig. 3 (Paper III) the patients displayed 
great individual variations in the cytokine levels. For most patients however, their individual 
levels were surprisingly similar before and after the 6 months ECP-course. The only 
significant changes in average concentration during the ECP course were a small increase in 
TGF-β in both patient groups and a small decrease in IL-17 in the GVHD patients, which can 
be in accordance with a supposed mechanism of Treg cell-mediated down-regulation of an 
immune reaction. The mean level of TGF-β was on average more than three times higher in 
the GVHD than the CTCL patients, and the GVHD patients also had the highest increase 
during the ECP course (Fig. 3B, Paper III). In spite of the great individual variations the 
cytokine profile was quite similar in the two patient groups for IL-4, IL-6, IL-10, IL-17 and 
IFN-γ. Th1 and Th17 are supposed to be the main effector T cells mediating of GVHD[140, 
141], and one might have expected their marker cytokines IFN-γ and IL-17, respectively, to 
be elevated especially in the GVHD patients. Nevertheless, these findings may emphasize that 
it is the local milieu and concentrations of cytokines that ultimately are decisive for immune 
regulation without necessarily being reflected in the serum concentrations. 
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We have looked especially for the relative concentration of Treg cells among the helper T 
cells (CD3+CD4+) in the two patient groups. We chose to define the Treg cells as; 
CD3+CD4+Foxp3+CD127-[142] and not to use the CD25 marker as it may be problematic to 
identify precisely the CD25high fraction which represents the original hallmark of Treg 
cells[94, 143]. In the present study, we found that among the healthy controls (HC) the 
fraction of Treg cells was on average 4,1%±1,9 (mean±SD), which is in coherence with 
previously reported percentage of the Treg cell subset[94, 144]. The fact that these cells are 
also predominantly CTLA4+ in both patient groups and HC seems to support their Treg 
identity. The most striking finding was that the Treg fraction in the GVHD patients was at a 
level close to the HC, whereas the CTCL patients had a Treg level more than twice as high 
(Fig. 4A, Paper III). Our finding of an elevated Treg fraction in the CTCL patients is at 
variance with the report from Tiemessen et al. who found equal Treg levels in CTCL patients 
and controls[120]. Klemke et al reported paucity of  Foxp3 cells in peripheral blood of Sèzary 
patients[145]. Our CTCL patients only include one Sèzary case so our finding may not 
necessarily be contrasting to this. It may seem to be a paradox that the GVHD patients have 
the highest serum concentration of TGF-β, but close to normal Treg counts in peripheral 
blood, whereas the CTCL patients have elevated Treg count, but low levels of TGF-β. One 
explanation could be that the GVHD patients may have activated Treg cells, and that these are 
mainly not in circulation, but have migrated into the tissues where the pathogenic alloreaction 
is taking place. We cannot really know how the distribution of circulating cells correlates to 
the total body distribution. Generally, the reported level of Treg cells in chronic GVHD 
remains inconclusive, with both increased[146] and decreased[147] levels reported, together 
with studies that demonstrate a normalization of the Treg cells after ECP[148]. In this study, 
the patients with GVHD had close to normal levels of Treg cells, although slightly elevated 
pre-treatment compared to the HC. After 6 months of ECP, this small difference was 
completely abolished. Miyara et al recently published a convincing study that shows that the 
CD4+Foxp3+ Treg cell population can be divided into three distinct subsets, based on the 
degree of Foxp3 and CD45RA expression[149]. These subpopulations are CD45RA-Foxp3high 
activated Treg cells (aTreg), and CD45RA+Foxp3low resting Treg cells (rTreg), both potently 
suppressive. They also describe a third population consisting of CD45RA-Foxp3low non-
suppressive Treg cells, secreting proinflammatory cytokines, such as IL-17. The latter may 
correspond to the activation-induced Foxp3+ cells that transiently express Foxp3, but lack 
suppressive properties. The key-findings of Miyara’s group are the demonstration of that 
CD45RA+ rTreg and CD45RA- aTreg cells represent a differentiation linage of the same T 
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cells, and that expression of CD45RA can be used to differentiate between the activation state 
of the subsets. Finally, they demonstrate that aTreg cells can suppress rTreg cells, thus 
creating a negative feedback loop to prevent further activation of resting Tregs. A reduction of 
naïve CD45RA+ Treg cells was also observed in our study, possibly reflecting an increase in 
the proportion of secondary, activated cells. Our findings of increased secondary cells are 
similar to those reported by Biagi et al[150]. Tiemessen et al found that Treg from CTCL 
patients who did not respond to ECP treatment were dysfunctional and expressed lower levels 
of Foxp3 than normal cells[120]. We could not detect by flow cytometry any lowered 
expression of Foxp3 in the CTCL patients, and we have not tested the Treg cells functionally. 
However, our findings of high Treg counts and low serum TGF-β in the CTCL patients could 
possibly be related to the findings of Berger’s[118] and Tiemessen’s[120] groups that the 
Treg population, or part of it, in the CTCL patients is pathological and dysfunctional. The 
slight, but significant increase in serum TGF-β and lowered Treg count following the ECP 
course could represent an effect of ECP towards normalization also in the CTCL patients. The 
patient materials that we present here are small, and even if our findings are supported by 
statistical significance, the conclusions should not be too far-fetched. However, it is 
reasonable to relate our results to the recent findings of Gjerdrum et al who demonstrated that 
the degree of Treg infiltration in CTCL was correlated to patient survival, and they suggested 
that Treg cells can directly suppress the function of malignant T cells[119]. We think that 
their findings also contradict that CTCL cells have a Treg phenotype as infiltrating CTCL 
cells should clearly not correlate positively to patient survival. We have here demonstrated an 
increasing serum concentration of TGF-β in both patient groups as a result of the ECP; in the 
GVHD patients also a reducing level of IL-17. This might point to an amplified Treg function, 
a finding recently confirmed in GVHD patients[151]. Parallel to this both patient groups 
exhibited a reduced primary (CD45RA+) fraction among the Treg cells following ECP. This 
could imply an antigen-driven expansion of secondary Treg cells. Elevated level of CD39 in 
both patient groups, and even significantly increasing in the GVHD patients following ECP 
could imply an elevated suppressive quality of the Treg cells. Of the GVHD patients 11 out of 
14 had responded well to the ECP therapy (Table 2, Paper III), whereas 13 out of 24 CTCL 
patients had responded, but to a more varying degree. Except for the 3 patients included in the 
study as RM, the remaining patients were considered as late-stage CTCL (Table 1, Paper III). 
When comparing the non-responding and responding patients one would expect to find 
increased CD39 expression as a sign of improved Treg cell function in the responding group. 
We were, however, not able to detect any differences in the CD39 expression, but both groups 
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displayed a small increase after ECP. This may indicate that additional factors mediating 
treatment success are involved, or perhaps that the patient material is too small to detect any 
difference. The especially elevated serum TGF-β in the GVHD patients could reflect the very 
strong immune reaction taking place in these patients. Even if seemingly not increased in 
number, the activation of the Treg cells may be strong to counterbalance the strong and 
destructive GVH reaction. Immunologically, CTCL supposedly imply a more indolent 
condition than GVHD, not activating the Treg cells strongly, but an elevated number of Treg 
cells might represent a homeostatic proliferative reaction evolving to curb the expansion of 
malignant T cells in accordance with the mentioned report by Gjerdrum et al. 
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Conclusions 
This thesis approaches different issues concerning the ECP treatment, and the main results 
and conclusions can be summarized in the following way, together with which aim they are 
intended cover (see Aims p.25-27): 
  
Paper I 
Seven patients were classified as responders to ECP. Nine patients were classified as non-
responders. This gives a response rate of 44%, and is somewhat lower than the observations 
made by other investigators. If we exclude the RM patients, the response rate is even lower in 
this material, 4/13 patients, i.e. 31%. This may be incidental due to the small size of the 
patient material (Aim 1). 
 
Neither T cell clonality nor any of the serum markers assessed pre-treatment could reliably 
predict the clinical response to ECP. A reduction in serum sIL-2R, neopterin and β2-M during 
the first course of ECP can however, add in the prediction of a better prognosis on the long 
run (Aim 2). 
 
Paper II 
Monocytes and immature DC become apoptotic within 72 hours when treated with ECP, the 
majority even earlier. Since monocytes and immature DC seem to have a reduced ability to 
differentiate after ECP treatment, it is likely that the therapeutic effect of ECP is caused by in 
vivo effects of reinfused apoptotic cells, rather than by infusion of monocytes induced to 
differentiate into immature DC (Aims 1 and 2). 
 
Monocytes and immature DC seem to tolerate doses of gamma irradiation that induce 
apoptosis in lymphocytes, and maintain their differentiating capability to the same extent as 
untreated cells (Aim 3). These findings validates that a one-step procedure based on 30Gy 
gamma irradiated cells instead of ECP treated cells ought to be tried when testing out the 
transimmunization model proposed by other investigators. 
 
Paper III 
The relative fraction of Treg cells was twice as high in the patients with CTCL, compared to 
both GVHD-patients and healthy controls (Aim 1), and could be interpreted as a response 
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involved in down-regulating the lymphoma cells. A reduction of Treg cells was observed in 
both patient groups during 6 months of treatment, but without reaching a statistically 
significant difference (Aim 2). The non-responding CTCL patients had on average a higher 
relative amount of Treg cells than the responding patients both before and after treatment, but 
the difference was not significant (Aim 3). Finally, we observed that the anti-inflammatory 
cytokine TGF-β was on average 3 times higher in GVHD than in CTCL. Both CTCL and 
GVHD patients had a small, but significant increase of TGF-β after 6 months of ECP 
treatment, whereas the GVHD patients additionally showed a decrease in IL-17, which is 
associated with inflammation (Aim 4). In conclusion, we think our data support the notion that 
the clinical effect of ECP in both GVHD and CTCL most probably is mediated by a 
strengthening of the Treg cell function. 
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Future aspects 
Patient survival would be a stronger parameter to follow up than clinical response measured 
as skin score improvement. So far, the patients included in this thesis are too few for such a 
follow up, but it should be considered when more patients get included. A predictive marker 
for response would naturally be of great benefit and should be searched for. 
 
Monocytes and dendritic cells were observed to undergo apoptosis within 72 hours after ECP 
therapy, the majority even earlier. It would, however, be interesting to do functional studies of 
the cells immediately after treatment. Are the treated cells capable to phagocytize and present 
engulfed antigen to the immune system before they die? 
 
We observed elevated numbers of Treg cells in the CTCL patients, and further 
characterization and isolation of these cells would be a natural next step as an attempt to 
determine the origin and function of the cells (especially cytokine production and suppressive 
capacity). 
 
As CTCL and GVHD are rather rare conditions, there are limited numbers of patients 
available. A larger study population seems essential to obtain more conclusive results, and 
inclusion in international multi-center studies should be an aim in the future. 
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Abstract Extracorporeal photochemotherapy (ECP) is a well established treatment for both
cutaneous T cell lymphoma (CTCL) and graft-versus-host disease (GVHD). However, the general
effector mechanism is not fully settled. Twenty-four patients with CTCL and 14 patients with
GVHD were included to assess the relative numbers of regulatory T cells (Treg) and any change in
the serum cytokine profile during 6 months of ECP therapy. The relative amount of Treg cells was
twice as high in CTCL compared to GVHD and healthy controls. TGF-β was on average three times
higher in GVHD than in CTCL. Both patient groups had a small but significant increase in TGF-β
after treatment. Our results indicate a strengthened Treg function as a result of ECP. Elevated
TGF-β may indicate high Treg activation in GVHD, whereas an increased number of Treg cells in
CTCL could be interpreted as a response that is involved in down-regulating the lymphoma cells.
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Extracorporeal photochemotherapy (ECP), or photopheresis,
was introduced by Edelson et al. in 1987 [1] as a treatment fored.
ma
lincutaneous T cell lymphomas (CTCL). Encouraged by the
promising results in CTCL, ECP has later been applied to a
variety of T cell mediated diseases, such as graft-versus-host
disease (GVHD) [2], preventing graft rejection in heart and
renal transplantation [3–5], as well as in other autoimmune
diseases [6,7]. The ECP procedure is based on leucapheresis,
followed by extracorporeal treatment of the leucocytes with
8-methoxypsoralen (8-MOP) and illumination with ultraviolet
light A (UVA) before being reinfused to the patient. The
therapeutic effect of ECP is supposed to be explained by 8-MOPand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
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ARTICLE IN PRESSbinding covalently to DNA in circulating lymphocytes when
illuminated with UVA. This ultimately leads to cell prolifera-
tion arrest and induction of apoptosis in the treated cells [8,9].
GVHD is a condition that evolves when allogeneic
immunocompetent cells are introduced into an immunoin-
competent host, and was first described by Billingham in
1959 [10]. The main occurrence is after haematopoietic cell
transplantation, but GVHD is also seen after solid organ
transplantations and blood transfusions. The pathophysiolo-
gy of GVHD is T cell recognition of target tissues as being
foreign with a subsequent induction of an inflammatory and
cytolytic response leading to injury. Regulatory T cells (Treg)
have been reported to protect against chronic cutaneous
GVHD [11]. Immunomodulation by phototherapeutic agents
has been proven beneficial for some patients, especially with
chronic GVHD in the skin. PUVA is most widely used, but
success has also been reported with ECP [12,13]. The effect
is thought to be mediated through triggering of certain
tolerance mechanisms such as inhibition of pro-inflammatory
cytokines, stimulation of Treg cells and production of anti-
inflammatory cytokines [14–16].
CTCL represents a group of low-grade, non-Hodgkins'
lymphomas, such as mycosis fungoides (MF) and Sezary
syndrome (SS). Approximately one half of the patients with
CTCL treated with ECP demonstrates a reduction in skin
score by at least 50% within 12 months of treatment, and is
categorized as responders [17]. A major problem with
clinical ECP in CTCL is that we still do not know which kind
of effect we aim at obtaining. Due to the findings of
monoclonal T cells in peripheral blood, one explanation has
been that ECP induces an anti-clonotypic cytolytic immunity
directly against the lymphoma cells [18]. An essential issue in
CTCL is whether ECP is inducing specific cytotoxicity against
the lymphoma cells, or alternatively inducing specific or non-
specific Treg cells controlling the CTCL proliferation. The
success obtained with priming dendritic cells in cancer
therapy could point to the first possibility [19], whereas the
effect of ECP in GVHD, transplant rejection and autoimmu-
nity favours the other view [2–7].
Treg cells constitute a subset of T cells with immunosup-
pressive properties, and identifying discriminatory cell-sur-
face markers for the characterization and isolation of Treg
cells has been a crucial goal for some time. Treg cells were first
identified as T helper cells (CD4+) that strongly expressed
CD25 (IL2-Rα), both in mice and humans [20,21]. In humans,
however, it has been shown that activated T cells generally up-
regulate CD25 expression [22], thus decreasing the purity of
Treg cell isolation by this marker and limiting its utility when
studying Treg cells. It is known that Treg cells express several
other characteristic molecules in addition to being
CD25high, such as glucocorticoid-induced tumour necrosis
factor receptor (GITR), cytotoxic T-lymphocyte antigen 4
(CTLA4) and L-selectin (CD62L). The above mentioned cell-
surface or intracellular molecules are, unfortunately, also
expressed in activated T cells, thus making an exclusive
isolation of viable Treg cells a substantial problem. At present
the transcription factor Forkhead box p3 (Foxp3) is considered
the most specific marker for Treg cells. This protein is,
however, intracellular and not available for isolation of living
cells. The search for Treg specific cell-surface markers
continues, and several candidates have recently been assessed
[23]. The importance of Foxp3 was demonstrated by showingPlease cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clinthat Foxp3-mutant mice have a Treg cell-deficiency and
develop a severe lymphoproliferative autoimmune syndrome
[24]. Similarly, humans lacking Foxp3 suffer fromanaggressive
autoimmune syndrome, known as immune dysregulation,
polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome,
a rare recessive disorder that results in early death [25]. When
first discovered in mice, Foxp3 was thought to exclusively
identify Treg cells also in humans, but recent evidence
supports that Foxp3 indeed can be induced upon T cell
activation, and that these Foxp3+ T effector cells are without
immunosuppressive properties. Hence, low expression of
specific cell-surfacemarkers should also be exploited to assess
and identify Treg cells, for instance, that they have low
expression of CD127 (known as IL7-Rα), whereas activated,
effector T cells are CD127high [26,27]. Treg cells are thought
to be capable of inhibiting immune responses against a variety
of antigens, including the ones expressed by malignant cells
[28]. In preventing autoimmune disease, the presence of Treg
cells is naturally thought to be beneficial, whereas in the
context of CTCL high numbers of these regulatory cells have
mainly been supposed to inhibit the surveillance and clearance
of tumour cells. Indeed, investigators have suggested that
there is an association between a high tumour burden or
tumour progression and an increase in Treg cells [29]. CD103,
an αEβ7 integrin that mediates T cell retention in the
epithelial compartment, has been shown to be an excellent
marker for identifying in vivo-activated (induced) Treg cells
[30,31]. These CD103+CD4+Foxp3+ Treg cells have been shown
to be more potent suppressors in autoimmune arthritis [30]
and in reversing chronic GVHD than primary CD4+CD25high
Treg cells [32]. CD39 is a member of the ectonucleoside
triphosphate diphosphohydrolase family, and is expressed on
the surface of various cells. Its function is to degrade ATP,
which acts as a “danger signal” that activates the immune
system, to AMP. In combination with CD73, another ectonu-
cleotidase, it results in the production of adenosine, that
exhibit inhibitory and antiproliferative effects. Recently, it
has been shown that CD39 is confined to a subset of the Treg
cells, thought to represent regulatory cells with effector/
memory-like properties. In the same study, the expression of
CD39 among the Treg cells was also reflected in the capacity to
degrade ATP, as well as in suppressive capacity [33]. CD45RA is
a surface marker of primary (naïve) T cells in contrast to
secondary (antigen-stimulated) T cells.
This study was performed to determine the relative
numbers of Treg cells, characterized by the phenotype
CD3+CD4+Foxp3+CD127−, prior to ECP and after 6 months of
ECP treatment in patients with CTCL or GVHD. Further
characterization was done to analyze the expression of
CTLA4, CD25, CD45RA, CD103 and CD39 among the Foxp3+
cells. In addition we studied whether there was a measurable
change towards a tolerogenic profile, by assessing the serum
concentrations of IL-4, IL-6, IL-10, IL-17, IFN-γ and TGF-β,
before and after 6 months of ECP treatment.Materials and methods
Study populations
Freeze-stored serum and peripheral blood mononuclear cells
(PBMC) from a total of 58 individuals were evaluated. Theand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
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GVHD (n=14) treated with ECP between 1993 and 2008, as
well as healthy controls obtained from blood donors (HC,
n=20). The CTCL and GVHD patients were evaluated before
treatment and after 6 months of ECP therapy. The stored
material was unfortunately not complete for all patients
when it came to the availability of both serum and PBMC
before and after 6 months of ECP treatment. Hence, 20/24
CTCL patients and 12/14 GVHD patients were assessed with
the cytokine assays, whereas 20/24 CTCL and 11/14 GVHD
patients were included in the flow cytometric analysis
(Tables 1 and 2).
CTCL patients
The clinical manifestations of the CTCL patients were
heterogeneous (Table 1). The included patients were all
erythrodermic when initiating ECP or immediately before
ECP started, and had skin biopsies “diagnostic of” or
“consistent with” mycosis fungoides (MF) (20/24), whereas
3/24 patients were histologically classified as “suspicious” of
MF, and included in the study as “Red man syndrome” (RM).
One patient had Sezary syndrome (SS), defined as having
more than 20% abnormal, cerebriform, circulating lympho-
cytes (Sezary cells) of the total leukocyte count in peripheralTable 1 CTCL patients treated with extracorporeal photochemo
Patient Age a/sex Diagnosis b Stage c TNMB c
1 82/M MF IIB T3NxM0B
2 40/M MF IIIB T4N1M0
3 77/M MF IIIA T4N0M0
4 63/M MF IIIA T4N0M0
5 76/F MF IIIA T4N0M0
6 75/M MF IIIA T4N0M0
7 66/M MF IVA T4N2M0
8 56/F MF IIIA T4N0M0
9 73/M MF IIIA T4N0M0
10 66/M SS IVA T4N3M0
11 64/M MF IVA T4N3M0
12 61/F MF IIIA T4N0M0
13 59/F MF IIIA T4N0M0
14 77/F MF IIIA T4N0M0
15 75/M MF IIIA T4N0M0
16 70/M MF IIIA T4N0M0
17 77/F MF IIIA T4N0M0
18 36/M MF IIIB T4N1M0
19 72/F MF NA NA
20 58/M MF IIIA T4N0M0
21 70/F RM
22 80/M RM
23 76/M RM
24 76/F MF IIIA T4N0M0
NA, not available.
a Age at ECP start.
b MF, mycosis fungoides; SS, Sezary syndrome; RM, Red man syndrom
c Staging according to Bunn and Lamberg [54]. Patients with RM have
d Skin score pre-treatment. ND, not done/available.
e CR, complete remission; PR, partial remission (N50% reduction in sk
no response/stable disease; PD, progressive disease (N25% increase in
f ✓ indicates the availability of stored serum or peripheral blood mo
analysis, respectively.
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treatment period, all patients initially received ECP as a
monotherapy. However, the patients in the non-responding
group, i.e., patients who lacked clinical response or had
progressive disease, received in addition to ECP interferon-
alfa after 6 months of ECP monotherapy, but without
improved effect on their clinical skin disease. The CTCL
patients were classified at initiation of ECP according to a
skin score test defined as the product of skin disease severity
score multiplied by percent affected body surface area [1].
The skin disease severity score is according to the following
scale: 0=normal, 1=barely detectable erythema and scal-
ing, 2=readily detectable erythema, edema and scaling,
3=marked erythema and exfoliation, and 4= fissuring,
maximal erythema, induration and tumours. This makes
400 (4×100%) the maximal total skin score. The clinical
response of the CTCL patients to ECP was defined as a
reduction in skin score by at least 50% as registered after 12
months of ECP treatment. Skin biopsies were taken of all
patients, and peripheral blood was examined for atypical
cells. Lymph node biopsies were performed on all patients
with palpable lymphadenopathy. X-ray or CT-scan of the
chest, as well as ultrasound or CT-scan of the abdomen, were
performed to evaluate clinical stage.therapy.
Skin score d Response e Serum f PBMC f
0 NA NR ✓ NA
B0 270 PD ✓ ✓
B0 356 MR ✓ ✓
B1 270 PR ✓ ✓
B1 400 NR ✓ ✓
B0 189 MR/PR ✓ ✓
B0 255 NR ✓ ✓
B0 144 MR ✓ ✓
B0 288 MR/PR ✓ ✓
B2 26 PD ✓ ✓
B0 285 NR ✓ ✓
B1 170 PR ✓ ✓
B0 285 NR ✓ ✓
B0 122 NR/PD ✓ ✓
B1 162 NR ✓ ✓
B0 249 NR ✓ ✓
B0 NA NR ✓ NA
B0 380 NR ✓ ✓
NA NR ✓ NA
B0 400 NR ✓ NA
300 PR/CR NA ✓
300 PR NA ✓
400 PR NA ✓
B0 300 PR NA ✓
e.
no indication for staging.
in score); MR, minor response (25–50% reduction in skin score); NR,
skin score).
nonuclear cells (PBMC) for cytokine assays or flow cytometric
and graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
Table 2 GVHD patients treated with extracorporeal photochemotherapy.
Patient Age a/
sex
Pre-treatment
(mg/week) b
6 months
(mg/week) b
GVHD/organ Response c Serumd PBMC d
Pred Cyclo Pred Cyclo
1 52/M 280 1400 52,5 1400 Oral/genital mucosa/eyes R ✓ ✓
2 35/M 35 1400 0 1400 Skin/oral mucosa/eyes R ✓ ✓
3 45/F 70 0 35 0 Skin/eyes R ✓ NA
4 25/M 0 1400 0 1400 Liver/oral mucosa/eyes NR ✓ ✓
5 21/M 0 0 0 0 Oral/genital mucosa R ✓ ✓
6 43/M 280 0 87,5 0 Skin NR ✓ ✓
7 62/F 0 700 0 700 NA NR ✓ NA
8 27/F 27,5 0 0 0 Skin/oral mucosa/eyes R ✓ NA
9 55/M 105 2625 0 2275 Oral mucosa R ✓ ✓
10 32/F 70 1400 35 1400 Oral/genital mucosa/eyes R ✓ ✓
11 48/F 110 0 52,5 0 Skin/oral mucosa/eyes R ✓ ✓
12 43/F 0 1400 0 1400 Oral mucosa R ✓ ✓
13 58/M 0 0 0 0 Skin/oral mucosa/eyes R NA ✓
14 21/M 0 0 0 0 Skin/eyes R NA ✓
NA, not available.
a Age at ECP start.
b Pred, prednisolone; Cyclo, cyclosporine.
c R, responder; NR, no response.
d ✓ indicates the availability of stored serum or peripheral blood mononuclear cells (PBMC) for cytokine assays or flow cytometric
analysis, respectively.
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A total of 14 patients with chronic GVHD after allogeneic
bone marrow transplantation were included in the study.
They had all been treated with bone marrow transplantation
for hematological malignancies, and received ECP either as
monotherapy or in combination with other immunosuppres-
sive drugs. See Table 2 for individual data of immunosup-
pressive treatment and clinical response.
Cells and reagents
For this retrospective study, blood and serum samples from
CTCL or GVHD patients were obtained immediately before
each ECP procedure. Serum was stored at −70 °C. Peripheral
blood mononuclear cells (PBMC) were isolated by centrifu-
gation on Lymphoprep (Axis-Shield, Oslo, Norway) according
to standard procedures, and stored in 10% DMSO in
RPMI1640/PHS at −135 °C. As healthy controls (HC), we
used frozen samples of PBMC that were isolated and stored as
described above, obtained from blood donors.
Cytokine assays
Serum stored at −70 °C, obtained pre-treatment and after 6
months of ECP treatment, was thawed and the concentrations
of IL-4, IL-6, IL-10, IL-17 and IFN-γ were simultaneously
measured in duplicates, using a Milliplex Human Cytokine/
Chemokine Immunoassay (Millipore Corp., Billerica, MA). The
concentration of TGF-β was measured, also in duplicates,
using a LINCOplex TGF-β1 Single Plex Kit (LINCO Research, St.
Charles, MO). Both kits were applied according to the
manufacturer's instructions. Data from the cytokine measure-
ments were then retrieved from a Luminex 100 IS analyzer
using the instrument software (Luminex Corp., Austin, TX).Please cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, ClinImmunophenotyping
Cells stored at −135 °C were thawed for immunophenotyp-
ing. Following the manufacturer's instructions, the cells were
stained with the following antibodies in five- or six-color
combinations: anti-CTLA4 APC, anti-CD3 FITC, anti-CD4 APC-
H7, anti-CD25 APC (all four obtained from BD Biosciences,
San Jose, CA), anti-CD103 PE-Cy5 (Abcam, Cambridge, UK),
anti-CD127 FITC, anti-CD45RA PE-Cy7, anti-CD3 PerCp-Cy5.5
and anti-CD39 PE-Cy7 (all four obtained from eBioscience,
San Diego, CA). For intracellular staining, a PE anti-human
Foxp3 Staining Set (clone PCH101) was used (also obtained
from eBioscience). Briefly, after thawing, the PBMCs were
washed with phosphate buffered saline with 0.1% bovine
serum albumin (PBS w/0.1% BSA) and stained for surface
antigens by incubation for 20 min at room temperature
protected from light. After washing with PBS w/0.1% BSA,
the cells were permeabilized with the provided Fix/Perm
buffer for 45 min at 4 °C, washed twice with Perm buffer and
stained for intracellular Foxp3 and CTLA4 at 4 °C for 30 min.
After intracellular staining, the cells were washed twice with
Perm buffer, and finally resuspended in 500 μl PBS w/0.1%
BSA for flow cytometric analysis.
Flow cytometry
After surface and intracellular staining as described above,
the cells were processed through a FACSCanto™ flow
cytometer (BD Biosciences), using forward vs. side scatter
properties to distinguish viable from dead cells. The T
lymphocytes were identified using anti-CD3, and a minimum
of 30,000 CD3+ events were acquired. With five- or six-color
staining the percentage of Treg cells (defined as CD3+CD4
+Foxp3+CD127−/CD3+CD4+ lymphocytes) was determined asand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
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background controls. Further characterization was done to
analyze the fraction of CTLA4, CD25, CD45RA, CD103 and
CD39 among the CD3+CD4+Foxp3+CD127− cells.
Statistical analysis
Patient samples were evaluated before and after 6 months of
ECP treatment. With SPSS 15.0 software (SPSS, Inc., Chicago,
IL), any differences between the patient groups were
evaluated using a two-tailed Mann–Whitney U-test, whereas
the Wilcoxon matched pairs test was used to evaluate
individual differences during treatment. The significance
level of the statistical tests (p-values) was set to b0.05. In
Figs. 4 and 5, only significant differences are displayed.
The study was approved by The Regional Medical Research
Ethics Committee of Central Norway and conducted accord-
ing to Declaration of Helsinki principles.
Results
Cytokine assays
Serum concentrations of IL-4, IL-6, IL-10, IL-17, IFN-γ and
TGF-β in patients with GVHD (n=12) and CTCL (n=20) were
evaluated before and after 6 months of ECP treatment. In the
CTCL patients there was a small but significant increase inFigure 1 Flow cytometric gating strategy. A region was set around
before gating on CD3+CD4+ double positive cells (2). Then, the
determined by using quadrants previously set with background contr
fraction of CD45RA (in this example), CD25, CTLA4, CD103 and CD39 a
from a healthy blood donor considered as representative.
Please cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clinmean TGF-β from 3.3 to 3.9 ng/ml during 6 months of ECP
treatment (pb0.01). No significant difference in the mean
serum concentrations of IL-4, IL-6, IL-10, IL-17 or IFN-γ was
found during the same period of ECP (Fig. 2). Further on, we
found no differences between the responding and non-
responding CTCL patients in the cytokine measurements (not
shown). As displayed in Fig. 3A, an increase in mean TGF-β
from 11.7 to 15.6 ng/ml was also found in the patients with
GVHD during 6 months of ECP treatment (pb0.05). In the
same patients, the mean concentration of IL-17 decreased
from an average of 41.7 to 23.5 pg/ml after 6 months of ECP
treatment compared to pre-treatment (pb0.05). As for the
CTCL patients, there was no significant change in the serum
concentrations of the remaining cytokines that were
evaluated. When comparing the two patients groups, we
observed that the GVHD patients had significantly higher
mean serum concentrations of TGF-β than the CTCL
patients: 11.7 vs. 3.3 ng/ml (pb0.01) pre-treatment and
15.6 vs. 3.9 ng/ml (pb0.01) after 6 months of ECP (Fig. 3B).
No differences were found between the two patient groups,
regarding IL-4, IL-6, IL-10, IL-17 or IFN-γ.Flow cytometric analysis of PBMC
Stored samples of PBMC from healthy controls (HC, n=20)
and patients with GVHD (n=11) or CTCL (n=20) were thawed
for immunophenotyping and flow cytometric analysis, tothe lymphocytes using the forward vs. side scatter properties (1),
expression of Foxp3+CD127− among the CD3+CD4+ cells was
ols (3). Finally, further characterization was done to analyze the
mong the Treg cells. Data displayed in this example are obtained
and graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
Figure 2 Individual serum cytokine profiles in CTCL. In the CTCL patients the serum concentration of TGF-β increased during 6
months of ECP treatment (pb0.01). Therewere no statistical differences in IL-17, IFN-γ, IL-6, IL-4 or IL-10 during the treatment period.
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of the total CD4+ T lymphocyte subset, pre-treatment and
after 6 months of ECP treatment. In the HC, the percentage
of Treg cells was on average 4.1%. In the peripheral blood of
the CTCL patients, the relative amount of Treg cells was
higher compared to the HC both before (11.7%, pb0.001)
and after ECP treatment (10.1%, pb0.001), as well as when
compared to the patients with GVHD (4.9% pre-treatment
and 4.1% after 6 months of ECP treatment, pb0.01) (Fig. 4A).
A slight but not significant decrease of the Treg cells was
observed during the treatment period in both patient groups.
The GVHD patients had only slightly elevated levels of Treg
cells pre-treatment, but the differences were not statisti-
cally significant compared to the HC (4.9% vs. 4.1%, p=0.44).
After 6 months of ECP treatment, the relative amount of
Treg cells seemed to further normalized (Fig. 4A).
The CTCL patients were categorized as ‘non-responders’
or ‘responders’ to ECP (see Table 1) in order to see whether
there were any differences in Treg cells. Pre-treatment,
both groups were significantly higher than the HC (14.8% and
8.5% vs. 4.1%, pb0.001 and pb0.01, respectively), and the
non-responders had on average a higher relative amount of
Treg cells than the responders, but the difference was not
significant (Fig. 4B). As described when assessing the CTCLPlease cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clinpatients without regard to their responder status, both the
non-responders and the responders had a slight decrease in
the percentage of Treg cells after 6 months of ECP treatment
(from 14.8% to 12.1% and from 8.5% to 8.0%, respectively).
Expression of CTLA4, CD103, CD45RA and CD39
among the Treg cells
Further characterization was done to analyze the expres-
sion of CTLA4, CD103, CD45RA and CD39 among the Treg
cells. CTLA4 was near equally expressed in the Treg cells of
CTCL (81.6%) and GVHD (75.6%) patients, as well as in the
HC (88.0%) (Fig 5A). As shown in Fig. 5B–D, a higher
percentage of the Treg cells in GVHD patients expressed
CD103 compared to the HC pre-treatment (43.8% vs. 33.6%,
pb0.01). There was a decrease in the expression of both
CD103 (31.1%) and CD45RA (from 64.8% to 52.3%) after 6
months of ECP treatment (both pb0.05), whereas the
expression of CD39 increased from 66.4% to 73.2%
(pb0.05). A similar trend, with a decrease in the expression
of CD103 and CD45RA and an increase in CD39, was also
observed among the Treg cells in the CTCL patients during
ECP therapy (Fig. 5B–D). No differences were found
between the responding and non-responding CTCL patientsand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
Figure 3 Individual serum cytokine profiles in GVHD. In the GVHD patients the serum concentration of TGF-β increased (pb0.05),
whereas IL-17 decreased (pb0.05) during 6 months of ECP treatment. There were no statistical differences in IFN-γ, IL-6, IL-4 or IL-10
during the treatment period (A). When comparing the two patient groups, the GVHD patients had significantly higher serum
concentrations of TGFβ than the patients with CTCL, both before and after 6 months of ECP treatment (pb0.01) (B). The columns
represent the mean, and the error bars display the standard deviation (SD).
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CD103 (not shown).
DiscussionCTCL and GVHD are the diseases that have been found most
widely accepted for therapy with ECP. Even if rarely
curative, ECP can give clinical improvement to both of
these conditions which are pathogenetically very different,
but have in common that they are very resistant to
conventional therapeutic regimens. In GVHD it may seem
easy to understand the supposed effector mechanism of ECP.
This disease is mainly mediated by allogeneic T effector cells
recognizing the transplant recipient as foreign, and with
skin, intestine and liver as main target organs for an
immunological attack. It is understandable that a therapy
that can improve the Treg function can down-regulate the
immunological attack and bring clinical alleviation to the
patient, and that this may be the probable effect of ECP.
When it comes to CTCL this issue is still not solved. What is
the biology of Treg cells in this condition, and what is thePlease cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clineffective mechanism mediated by ECP? The explanation that
could seem to be the most likely possibility is that ECP
strengthen a T cell cytolytic effect on the CTCL analogous to
what can be obtained by immunotherapy of solid tumors
[19]. It seems paradoxical, however, that ECP should
improve a T cell regulatory function in one kind of patients
and a cytolytic one in another. This is further complicated by
the findings of Berger et al. that the CTCL cells can by
stimulation convert into a Treg phenotype [36], and
Tiemessen et al. have demonstrated that Treg cells in late
stage CTCL are nonfunctional [37]. The potential mechan-
isms of immune regulation with ECP, which imply infusion of
apoptotic dying cells, have recently been reviewed [15]. In
addition to stimulation of Treg cells, inhibition of pro-
inflammatory cytokines, such as IL-1, IL-6 and TNFα, as well
as production of anti-inflammatory cytokines, such as TGF-β
and IL-10, have been reported [38–41]. The appropriate
concentrations of these cytokines may regulate and decrease
the immune response at inflammatory sites.
The present study was designed to make a comparison
between two patient groups, CTCL and GVHD, submitted to
the same kind of ECP therapy during a parallel time course ofand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
Figure 4 Relative mean percentage of Treg cells in CTCL and
GVHD. Treg cells were elevated in the CTCL patients, compared
to both the HC and GVHD patients (pb0.001 and pb0.01,
respectively) (A). The CTCL patients were categorized as ‘non-
responders’ or ‘responders.’ Both groups had elevated Treg cells
compared to the HC (pb0.001 and pb0.01). Non-responders had
a higher mean of Treg cells than responders, but not significantly
(B). The columns represent the mean, and the error bars display
the standard deviation (SD).
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well to the ECP therapy (Table 2), whereas 13 out of 24 CTCL
patients had responded but to a more varying degree. Except
for the three patients included in the study as RM, the
remaining patients were considered as late-stage CTCL
(Table 1). We chose to test freeze-stored serum and PBMC
samples collected at start and ending of the standard 6-
month course of ECP. The serums were tested for a cytokine
profile representing the three kinds of T helper effector
cells, Th1, Th2 and Th17, as well as Treg cells. As will be seen
from Figs. 2 and 3 the patients displayed great individual
variations in the cytokine levels. For most patients, however,
their individual levels were surprisingly similar before and
after the 6 months of ECP course. The only significant
changes in average concentration during the ECP course
were a small increase in TGF-β in both patient groups and a
small decrease in IL-17 in the GVHD patients, which can be in
accordance with a supposed mechanism of Treg cell-
mediated down-regulation of an immune reaction. The
mean level of TGF-β was on average more than three times
higher in the GVHD than the CTCL patients, and the GVHD
patients also had the highest increase during the ECP course
(Fig. 3B). In spite of the great individual variations the
cytokine profile was quite similar in the two patient groupsPlease cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clinfor IL-4, IL-6, IL-10, IL-17 and IFN-γ. Th1 and Th17 are
supposed to be the main T effector cells mediating GVHD
[42,43], and one might have expected their marker cytokines
IFN-γ and IL-17, respectively, to be elevated especially in
the GVHD patients. Nevertheless, these findings may
emphasize that it is the local milieu and concentrations of
cytokines that ultimately are decisive for immune regulation
without necessarily being reflected in the serum
concentrations.
We have looked especially for the relative concentra-
tion of Treg cells among the T helper cells (CD3+CD4+) in
the two patient groups. We chose to define the Treg cells
as CD3+CD4+Foxp3+CD127− [44] and not to use the CD25
marker as it may be problematic to identify precisely the
CD25high fraction which represents the original hallmark
of Treg cells [21,45]. Due to the retrospective design, we
did not have data on absolute cell counts and are
therefore only assessing the relative changes in the cell
populations. In the present study, we found that among
the healthy controls (HC) the fraction of Treg cells was on
average 4.1±1.9% (mean±SD), which is in coherence with
previously reported percentage of the Treg cell subset
[21,46]. The fact that these cells are also predominantly
CTLA4+ in both patient groups and HC seems to support
their Treg identity. The most striking finding was that the
Treg fraction in the GVHD patients was at a level close to
the HC, whereas the CTCL patients had a Treg level more
than twice as high (Fig. 4A). Our finding of an elevated
Treg fraction in the CTCL patients is at variance with the
report from Tiemessen et al. who found equal Treg levels
in CTCL patients and controls [37]. Klemke et al. reported
paucity of Foxp3 cells in peripheral blood of Sezary
patients [47]. Our CTCL patients only include one Sezary
case so our finding may not necessarily be contrasting to
this. It may seem to be a paradox that the GVHD patients
have the highest serum concentration of TGF-β, but close
to normal Treg counts in peripheral blood, whereas the
CTCL patients have elevated Treg count, but low levels of
TGF-β. One explanation could be that the GVHD patients
may have activated Treg cells, and that these are mainly
not in circulation, but have migrated into the tissues
where the pathogenic alloreaction is taking place. We
cannot really know how the distribution of circulating
cells correlates to the total body distribution. Generally,
the reported level of Treg cells in chronic GVHD remains
inconclusive, with both increased [48] and decreased [49]
levels reported, together with studies that demonstrate a
normalization of the Treg cells after ECP [50]. In this
study, the patients with GVHD had close to normal levels
of Treg cells, although slightly elevated pre-treatment
compared to the HC. After 6 months of ECP, this small
difference was completely abolished. A reduction in naïve
CD45RA+ Treg cells was also observed, possibly reflecting
an increase in the proportion of secondary, memory cells.
Our findings of increased secondary cells are similar to
those reported by Biagi et al. [51]. Tiemessen et al. found
that Treg cells from CTCL patients who did not respond to
ECP treatment were dysfunctional and expressed lower
levels of Foxp3 than normal cells [37]. We could not
detect by flow cytometry any lowered expression of Foxp3
in the CTCL patients, and we have not tested the Treg
cells functionally. However, our findings of high Tregand graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
Figure 5 Functional markers on Treg cells. CTLA4 was near equally expressed on Treg cells in patients and HC (A). CD103 (B) and
CD45RA (C) displayed a decrease as result of ECP while CD39 showed a slight increase (D). The columns represent the mean, and the
error bars display the standard deviation (SD).
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possibly be related to the findings of Berger's [36] and
Tiemessen's [37] groups that the Treg population, or part
of it, in the CTCL patients is pathological and dysfunc-
tional explaining the lack of tumor control seen in
progressive CTCL disease. The slight but significant
increase in serum TGF-β and lowered Treg count following
the ECP course could represent an effect of ECP towards
normalization also in the CTCL patients. The patient
materials that we present here are small, and even if our
findings are supported by statistical significance, the
conclusions should not be too far-fetched. However, it is
reasonable to relate our results to the recent findings of
Gjerdrum et al. who demonstrated that the degree of
Treg infiltration in CTCL was correlated to patient
survival, and they suggested that Treg cells can directly
suppress the function of malignant T cells [52]. We think
that their findings also contradict that CTCL cells have a
Treg phenotype, as infiltrating lymphoma cells should
clearly not correlate positively to patient survival. We
have here demonstrated an increasing serum concentra-
tion of TGF-β in both patient groups as a result of the
ECP; in the GVHD patients also a reducing level of IL-17.
This might point to an amplified Treg function, a notion
recently confirmed in GVHD patients [53]. Parallel to this
both patient groups exhibited a reduced primary (CD45RA
+) fraction among the Treg cells following ECP. This could
imply an antigen-driven expansion of secondary Treg cells.
Elevated level of CD39 in both patient groups, and evenPlease cite this article as: V. Rao, et al., Cutaneous T cell lymphoma
extracorporeal photochemotherapy on Foxp3+ regulatory T cells, Clinsignificantly increasing in the GVHD patients following
ECP, could imply an elevated suppressive quality of the
Treg cells. When comparing the responding and non-
responding patients, however, we were not able to detect
any differences in the CD39 expression, indicating that
additional factors mediating treatment success are in-
volved and should be searched for. The especially
elevated serum TGF-β in the GVHD patients could reflect
the very strong immune reaction taking place in these
patients. Even if seemingly not increased in number, the
activation of the Treg cells may be strong to counterbal-
ance the strong and destructive GVH reaction. Immuno-
logically, CTCL supposedly implies a more indolent
condition than GVHD, not activating the Treg cells
strongly, but an elevated number of Treg cells might
represent a homeostatic proliferative reaction evolving to
curb the expansion of malignant T cells in accordance
with the mentioned report by Gjerdrum et al. Further
investigations including functional suppression assays of
isolated patient Treg cells are required to ultimately
decide whether ECP strengthens the suppressive capacity.Conclusion
We think our data suggest that the clinical effect of ECP in
both graft-versus-host disease and in cutaneous T cell
lymphoma is mediated by a strengthening of the regulatory
T cell function.and graft-versus-host disease: A comparison of in vivo effects of
. Immunol. (2009), doi:10.1016/j.clim.2009.08.016
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